Document:

Exhibit 10.1

 

SETTLEMENT TERM SHEET

 

		1.	Introduction

 

		a)	This binding term sheet (“Term Sheet”), dated as of April 15, 2019, is entered into
by the parties that are signatories hereto in connection with the consolidated action styled In re Medley Capital Corporation
Stockholder Litigation, C.A. No. 2019-0100-KSJM (the “Class Action”).

 

		b)	This Term Sheet memorializes an agreement-in-principle between FrontFour Capital Group LLC (“FFCG”)
and FrontFour Master Fund, Ltd. (“FFMF,” together with FFCG, “FrontFour” or “Plaintiffs”),
on behalf of themselves and a class of similarly situated stockholders of Medley Capital Corporation (“MCC” or the
“Company”), on the one hand, and Brook Taube, Seth Taube and Jeff Tonkel (the “Management Individual Defendants”),
Mark Lerdal, Karin Hirtler-Garvey, John E. Mack and Arthur S. Ainsberg (the “MCC Special Committee Defendants” and,
together with the Management Individual Defendants, the “MCC Board Defendants”), and MCC, MCC Advisors LLC (“MCC
Advisors”), Medley LLC and Medley Group LLC (“Medley Group” and with the MCC Board Defendants, MCC, MCC Advisors
and Medley LLC, the “Defendants”), on the other hand. Medley Management, Inc. (“MDLY”) has concurrently
entered into a Rider to this Term Sheet, attached hereto as Exhibit A.

 

		c)	The parties agree to cooperate and use their best efforts to reduce this agreement-in-principle
to a definitive stipulation of settlement (the “Settlement Stipulation”) on or before April 30, 2019, and to obtain
approval of the Court of Chancery as soon as reasonably practicable thereafter.

 

		d)	The parties shall provide this Term Sheet to the Special Committee and Board of Directors of Sierra
Income Corporation (“SIC”). The parties recognize that SIC’s participation and agreement will be necessary in
order to enter into any amendment of the MCC Merger Agreement (as defined below) and the MDLY Merger Agreement (as defined below)
in connection with the Settlement Stipulation as well as certain other post-closing arrangements or agreements contemplated hereby
(including Section 4 hereof). MCC agrees to use reasonable efforts to procure such participation by SIC (it being understood and
acknowledged by the parties that SIC’s consent, which it may provide in its sole discretion, will be required to implement
or effect certain of the terms contemplated by this Term Sheet including, but not limited to, the amendments to the MCC Merger
Agreement and the MDLY Merger Agreement contemplated by Section 2 and certain components of the Governance Agreement contemplated
by Section 4).

 

		2.	Curative Sale Process

 

		a.	Actions Requiring Merger Agreement Amendments

 

		i.	Market Check. As soon as reasonably practicable
after the execution of this Term Sheet, MCC shall:

 

		1.	Use reasonable efforts to obtain, on or prior to April
19, 2019, SIC’s agreement and MDLY’s consent to amend the Agreement and Plan of Merger between MCC and SIC dated as
of August 9, 2018 (the “MCC Merger Agreement”) to delete (or appropriately amend, waive or modify to the extent practicable)
Section 7.10 and modify Article 9 thereof to permit the MCC Special Committee to terminate the MCC Merger Agreement if the MCC
Special Committee concludes in its sole and absolute discretion that MCC should pursue a strategic alternative that the MCC Special
Committee concludes in its sole and absolute discretion is superior to the transaction contemplated by the MCC Merger Agreement.
The termination of the MCC Merger Agreement during the Go-Shop Period (defined below) shall not trigger a termination fee or any
other payment.

 

    1

     

    

 

		2.	empower and direct the MCC Special Committee to retain
at MCC’s expense an independent investment bank of its choosing (the “Go-Shop Banker”) to solicit strategic
alternatives for MCC upon either the amendment or waiver of the MCC Merger Agreement as contemplated by Section 1(a)(i) above,
or the termination of the MCC Merger Agreement.

 

		3.	empower and direct the MCC Special Committee and its
advisors to conduct a “Go-Shop” process whereby they will, upon either the amendment or waiver of the MCC Merger Agreement
as contemplated by Section 1(a)(i) above, or termination of the MCC Merger Agreement, solicit the making, submission and announcement
of, and encourage, facilitate and assist, any proposal or inquiry that constitutes, or is reasonably expected to lead to, an alternative
proposal; subject to the entry into, and in accordance with, a confidentiality agreement, the MCC Special Committee, in its discretion,
may furnish to any person (and its representatives and financing sources subject to the terms and obligations of such confidentiality
agreement applicable to such person) any non-public information relating to MCC or afford to any such person (and such representatives
and financing sources) access to the business, properties, assets, books, records and other non-public information, and to any
personnel, of MCC, in any such case with the intent to induce the making, submission and announcement of, and to encourage, facilitate
and assist, any proposal or inquiry that constitutes, or is reasonably expected to lead to, an alternative proposal or any inquiries
or the making of any proposal that would reasonably be expected to lead to an alternative proposal. The Go-Shop process shall
begin upon the retention of the Go-Shop Banker and shall conclude no sooner than sixty-days thereafter (the “Go-Shop Period”).
Traditional fiduciary out language will be added to the MCC Merger Agreement to address the time period after the Go-Shop has
concluded.

 

    2

     

    

 

		4.	Neither the members of the MCC Special Committee nor
their advisors shall disclose the identity of the participants in the Go-Shop process or the nature or amount of any proposals
submitted by those participants to the other MCC directors or anyone else until the MCC Special Committee has reached a final
decision on the results of the Go-Shop and presents its findings to the full MCC Board of Directors (the “MCC Board”),
unless the MCC Special Committee determines in its discretion that (A) disclosing such information prior to that time is consistent
with its members’ fiduciary duties, or (B) disclosing such information to the management of MCC and MCC’s advisors
is reasonably necessary or advisable in order to conduct the Go-Shop process in an effective, orderly and timely manner (including,
but not limited to, the due diligence process to be conducted by participants).

 

		ii.	Extension of the Outside Date. As soon as practicable
after the execution of this Term Sheet, MCC shall use reasonable efforts to obtain, respectively, SIC’s agreement and MDLY’s
consent to amend (or otherwise to waive or extend the time for the performance of the applicable provisions of) both the MCC Merger
Agreement and the Agreement and Plan of Merger between MDLY and SIC dated as of August 9, 2018 (the “MDLY Merger Agreement”)
to extend the Outside Date in each agreement until October 31, 2019.

 

		iii.	Consideration Adjustments. MCC shall use reasonable
efforts to cause SIC to agree to amend the payment mechanics in the MDLY Merger Agreement and MCC Merger Agreement contemplated
above to provide that if the transaction contemplated by the MCC Merger Agreement closes on its revised terms, the Settlement
Amount (defined below) will be paid to an escrow account which shall be distributed to eligible members of the Class (defined
below) in accordance with the Settlement Stipulation described below. Defendants shall agree to such adjustments to the payment
mechanics, but shall not be obligated to agree to any other adjustments or payments.

 

		b.	Other Actions.

 

		i.	Corrective disclosures. As soon as reasonably
practicable after the execution of this Term Sheet, Defendants and Plaintiffs shall work in good faith to agree upon supplemental
disclosures that MCC shall disseminate to satisfy the Court’s March 11, 2019 memorandum opinion and which will also clarify
that the echo voting will be calculated without regard to broker non-votes and abstentions.

 

		ii.	Waiver of Standstills. As soon as reasonably
practicable after the execution of this Term Sheet, Defendants shall take reasonable efforts to obtain the waiver of and/or release
of any potential counterparty of MCC from any applicable standstill or other agreements that would in any way inhibit or restrict
the potential counterparty’s participation in MCC’s exploration of strategic alternatives.

 

    3

     

    

 

		3.	Settlement Provisions

 

		a.	Stay of Class Action. Upon the execution of this Term Sheet, the parties shall submit a
stipulation and proposed order staying the Class Action, except for steps necessary to implement the settlement contemplated by
this Term Sheet.

 

		b.	SDNY Litigation. Upon the execution of this Term Sheet, Defendants shall take all steps
necessary to dismiss the litigation pending in the United States District Court for the Southern District of New York (the “Federal
Action”) without prejudice.

 

		c.	Class Definition. The Settlement Stipulation shall provide for the certification of a “Class” consisting
of all record and beneficial owners of MCC common stock at any time between and including August 9, 2018 and the later of (x) the
closing of the transaction contemplated by the revised MCC Merger Agreement or any alternative transaction and (y) the termination
of the revised MCC Merger Agreement (the “Class Period”), together with their successors and assigns, but excluding
the named defendants in the Class Action, and any person, firm, trust, corporation or other entity related to or affiliated with
any of the named defendants in the Class Action. In the event the Court of Chancery declines to permit the Class Period contemplated
above, the parties shall redefine the Class Period so that it covers a period acceptable to the Court; provided, that, the parties
shall not be obligated to agree to a settlement where the close of the class period defined by the Court is a date earlier than
the date that MCC files with the SEC a Report on Form 8-K disclosing that the parties have entered into this Term Sheet.

 

		d.	Releases. The Settlement Stipulation shall provide for a mutual release between and among Plaintiffs and the Class,
on the one hand, and the Defendants and MDLY on the other, of all claims that were or could have been asserted in the Class Action,
including, without limitation, all claims arising out of or relating to (i) the transactions contemplated by the MCC Merger Agreement
and/or the revised MCC Merger Agreement (including any actions, deliberations and negotiations relating thereto); (ii) the MDLY
Merger Agreement (including any actions, deliberations and negotiations relating thereto); (iii) the disclosures regarding those
transactions; (iv) the fiduciary duties or obligations of the Defendants and MDLY in connection with the review of strategic alternatives
available to MCC; (v) the vote or any adjournment of the vote of MCC stockholders on the transaction contemplated by the MCC Merger
Agreement; and (vi) proxy solicitation efforts in connection with the votes of the MCC stockholders on the transaction contemplated
by the MCC Merger Agreement. Defendants and MDLY shall also release all claims arising out of or relating to the prosecution and
settlement of the Class Action and all claims that were or could have been asserted in the Federal Action (other than claims against
NextPoint), and Plaintiffs and the Class shall release all claims arising out of or relating to the prosecution and settlement
of the Federal Action.

 

		e.	Notice of Settlement. The Settlement Stipulation shall provide for the dissemination of notice of the settlement to
the Class (the “Notice of Settlement”). MCC shall initially pay the costs of the disseminating the notice of settlement,
but it shall be reimbursed out of the Settlement Fund if one is created as described below.

 

    4

     

    

 

		f.	Settlement Amount. The Settlement Stipulation shall provide that, if the transaction contemplated by the revised MCC
Merger Agreement closes, then immediately after the closing, defendants in the FrontFour Action shall cause the contribution of
$17 million in cash and $30,000,000 of SIC stock, the number of shares of which is to be calculated using the pro forma NAV reported
in the future proxy supplement describing the amendments to the MCC Merger Agreement (the “Settlement Amount”), 1
to a settlement fund (the “Settlement Fund”), which shall be distributed to eligible members of the Class as described
below. For the avoidance of doubt, in no event shall MDLY be responsible for the payment of any portion of the Settlement Amount.

 

		g.	Waterfall. The Settlement Fund shall be distributed to members of the Class who held stock as of the closing of the
transactions contemplated by the revised MCC Merger Agreement, after deductions sufficient to cover expenses necessary to (i) reimburse
MCC for the costs of disseminating the Notice of Settlement, and (ii) cover the costs of administrating the Settlement Fund.

 

		h.	Attorneys’ Fees/Expenses. MCC or its successor shall pay any attorneys’ fees and expenses awarded by the
Court to Plaintiffs’ Counsel. Attorneys’ fees and expenses shall not be paid out of or otherwise deducted from the
Settlement Fund.

 

		4.	Cooperation/Governance Agreements.

 

		a.	Immediately upon execution of this Term Sheet, MCC and the MCC Board shall take all steps necessary to:

 

		i.	Add David Lorber and Lowell Robinson to the MCC Board,
each of David Lorber and Lowell Robinson having submitted to interviews with the Nominating and Corporate Governance Committee
of MCC beforehand and provided to the Company all such information (including a completed nominee director questionnaire) as may
be reasonably required in connection with assessing their respective eligibility, independence or other similar criteria pursuant
to applicable law and securities and stock exchange regulations. Lowell Robinson shall be added to the class of directors up for
election in 2020. David Lorber shall be added to the class of directors up for election in 2021. David Lorber and Lowell Robinson
shall be entitled to the same advancement and indemnification rights and insurance coverage as the other members of the MCC Board.

 

		ii.	Reconstitute the MCC Special Committee so that it
consists of David Lorber (Chair), Arthur Ainsberg, Karin Hirtler-Garvey and Lowell Robinson.

 

		iii.	Reconstitute the MCC Nominating and Corporate Governance
Committee so that it consists of David Lorber, Arthur Ainsberg (Chair), Karin Hirtler-Garvey; reconstitute the Compensation Committee
so that it consists of David Lorber, Arthur Ainsberg, Karin Hirtler-Garvey (Chair); and reconstitute the Audit Committee so that
it consists of Lowell Robinson, Arthur Ainsberg and Karin Hirtler-Garvey (Chair).

 

		iv.	Fix the size of the MCC Board at seven.

 

 

1
For example, if calculated as of the date of this Term Sheet using the NAV of SIC as of December 31, 2018, which was $6.72 per
share, as the pro forma NAV, $30,000,000 translates to 4,464,286 shares.

 

    5

     

    

 

		b.	The parties shall, as soon as reasonably practicable following the execution of this Term Sheet, enter into a Governance Agreement
that provides that:

 

		i.	FrontFour shall have customary replacement rights
with respect to the MCC Board seats held by David Lorber and Lowell Robinson through the end of the Standstill Period (defined
below). In the event that the transactions contemplated by the revised MCC Merger Agreement are consummated, MCC shall present
to SIC its proposal of the two independent directors recommended by the MCC Special Committee to join the Combined Company Board,
one of whom shall be Lowell Robinson.

 

		ii.	The Governance Agreement shall include a representation
that FrontFour is the beneficial owner of 1,674,962.329 shares of MCC common stock and a covenant by FrontFour to retain beneficial
ownership of such shares, including the sole authority to vote such shares, through the date of the stockholder meeting to approve
the MCC Merger Agreement (including any adjournments or postponements thereof). At any stockholder meeting to approve the MCC
Merger Agreement FrontFour shall vote in favor of the transactions contemplated by the revised MCC Merger Agreement. FrontFour
shall also vote at any stockholder meeting of the Combined Company or MCC (as applicable) during the Standstill Period (i) in
favor of the election of MCC’s or the Combined Company’s nominees to the MCC Board or the Combined Company Board (as
the case may be), and (ii) against any nominees for director not recommended by the MCC Board or the Combined Company Board (as
the case may be). With respect to any other stockholder proposals or other business presented at any stockholder meeting of the
Combined Company or MCC (as applicable) during the Standstill Period, FrontFour shall vote either (A) in accordance with the MCC
Board’s or the Combined Company Board’s (as the case may be) recommendation or (B) in accordance with the recommendation
of ISS (other than proposals in connection with or that are inconsistent with its support of the revised MCC Merger Agreement),
provided, however, that FrontFour shall be permitted to vote in its sole discretion with respect to any publicly
announced proposals (other than proposals in connection with or that are inconsistent with its support of the revised MCC Merger
Agreement) for a merger, acquisition, disposition of all or substantially all of the assets of MCC or the Combined Company (as
applicable) or other business combination or extraordinary transaction for MCC or the Combined Company (as applicable) requiring
a vote of stockholders of MCC or the Combined Company (as applicable).

 

    6

     

    

 

		iii.	FrontFour shall agree to customary standstill provisions
that shall extend from the execution of the Governance Agreement through (1) with respect to MCC, until the closing of the transactions
contemplated by the revised MCC Merger Agreement or, in the event that the MCC Merger Agreement is terminated, until the earlier
of (A) January 1, 2020, and (B) thirty (30) days prior to the deadline (the “MCC Deadline”) for stockholders to submit
director nominations not for inclusion in MCC’s proxy statement in connection with MCC’s 2020 annual meeting of stockholders
and (2) with respect to SIC, as the surviving company solely in the event that the transactions contemplated by the revised MCC
Merger Agreement are consummated (the “Combined Company”), until the earlier of (A) January 1, 2020, and (B) thirty
(30) days prior to the deadline (the “Combined Company Deadline”) for stockholders to submit director nominations
not for inclusion in the Combined Company’s proxy statement in connection with the Combined Company’s 2020 annual
meeting of stockholders (the “Standstill Period”). MCC will provide FrontFour with advance written notice of the MCC
Deadline at least forty-five (45) days prior to the MCC Deadline. In the event that the transactions contemplated by the revised
MCC Merger Agreement are consummated, the Combined Company will provide FrontFour with advance written notice of the Combined
Company Deadline at least forty-five (45) days prior to the Combined Company Deadline.

 

		iv.	MCC and FrontFour shall issue a mutually agreeable
press release supportive of the revised MCC Merger Agreement and the transactions contemplated thereby.

 

		v.	Following execution of a revised MCC Merger Agreement,
unless the MCC Special Committee elects to terminate the MCC Merger Agreement following the Go-Shop as contemplated in Section
1(a) above, FrontFour, by and through David Lorber, shall support MCC’s efforts with respect to obtaining the SEC exemptive
relief contemplated by Section 5, the support of proxy advisory firms for the transaction contemplated by the revised MCC Merger
Agreement and any other reasonably requested advocacy for such transaction.

 

		c.	Upon the execution of this Term Sheet, FrontFour shall immediately withdraw their candidates nominated for election at MCC’s
2019 annual stockholder meeting.

 

		5.	SEC Approval

 

The parties shall submit this Term Sheet
and all documents executed in connection with settlement of the Class Action, including but not limited to the Settlement Stipulation,
to the SEC and shall exercise reasonable efforts to secure SEC exemptive relief sufficient to permit the implementation of the
settlement and the closing of the transactions contemplated by the revised MCC Merger Agreement and the MDLY Merger Agreement.

 

		6.	Miscellaneous Provisions

 

		a.	This Term Sheet constitutes the entire agreement among the parties with respect to the settlement
contemplated hereby, supersedes all written or oral communications, agreements or understandings that may have existed regarding
the settlement prior to the execution of this Term Sheet, and may be waived, modified or amended only by a writing signed by all
the parties.  This Term Sheet contains the substantive terms of the settlement.  The parties agree to negotiate
and document the settlement in good faith.  Notwithstanding anything to the contrary in this Term Sheet, nothing contained
herein shall obligate any party to agree to any other modifications, amendments, waivers, or revisions to the terms of
the MCC Merger Agreement or MDLY Merger Agreement except as expressly set forth herein, and the failure of the Defendants
to reach agreement with each other or SIC on a revised MCC Merger Agreement and/or a revised MDLY Merger Agreement shall not constitute
a breach of this Term Sheet. FrontFour further covenants not to commence litigation or otherwise assert any claim against any Defendant
based on the inability of the parties to agree on a revised MCC Merger Agreement and/or a revised MDLY Merger Agreement, other
than due to a failure of any Defendant to exercise the reasonable efforts set forth herein. The parties further acknowledge that,
subject to the provisions and limitations set forth herein (including in Section 1) and the express understanding of the
parties that SIC’s participation, cooperation and agreement (which it may withhold in its sole discretion) shall ultimately
be required for any amendment of the MCC Merger Agreement and the MDLY Merger Agreement and to effect all other applicable provisions
hereof that contemplate the participation, cooperation and agreement by SIC this Term Sheet is binding.

 

    7

     

    

 

		b.	In the event that the amendments to MDLY Merger Agreement and MCC Merger Agreement contemplated
herein have not been entered into on or prior to May 15, 2019, each party hereto may elect, in writing, to terminate this Term
Sheet. Following such termination, this Term Sheet shall forthwith be of no further force and effect except that the provisions
of Section 4 (Cooperation/Governance Agreements) and Section 6 (Miscellaneous Provisions) shall survive any such termination.

 

		c.	This Term Sheet shall be governed by and construed in accordance with the laws of the state of
Delaware, without regard to conflict of laws principles. Each of the parties (i) irrevocably submits to the personal jurisdiction
of any state court sitting in Wilmington, Delaware, as well as to the jurisdiction of all courts to which an appeal may be taken
from such courts, in any suit, action or proceeding to enforce this Term Sheet, (ii) agrees that all claims in respect of such
suit, action or proceeding shall be brought, heard and determined exclusively in the Delaware Court of Chancery (provided that,
in the event that subject matter jurisdiction is unavailable in that court, then all such claims shall be brought, heard and determined
exclusively in any other state court sitting in Wilmington, Delaware), (iii) agrees that it shall not attempt to deny or defeat
such personal jurisdiction by motion or other request for leave from such court, (iv) agrees not to bring any action or proceeding
to enforce this Term Sheet in any other court, and (v) expressly waives, and agrees not to plead or to make any claim that any
such action or proceeding is subject (in whole or in part) to a jury trial. Each of the parties waives any defense of inconvenient
forum to the maintenance of any action or proceeding brought in accordance with this paragraph c.

 

		d.	This Term Sheet may be executed in counterparts and, as executed shall constitute one agreement
binding on all of the parties hereto notwithstanding that all said parties are not signatory to the original or same counterpart.
An electronic document, pdf, facsimile, telecopy or other reproduction of this Term Sheet may be executed by the parties and shall
be considered valid, binding and effective for all purposes.

 

[Signature Pages Follow]

 

    8

     

    

 

	 	By:	/s/ Brook Taube
	 	 	Brook Taube
	 	 	 
	 	By:	/s/ Seth Taube
	 	 	Seth Taube
	 	 	 
	 	By:	/s/ Jeff Tonkel
	 	 	Jeff Tonkel
	 	 	 
	 	By:	/s/ Mark Lerdal
	 	 	Mark Lerdal
	 	 	 
	 	By:	/s/ Karin Hirtler-Garvey
	 	 	Karin Hirtler-Garvey
	 	 	 
	 	By:	/s/ John E. Mack
	 	 	John E. Mack
	 	 	 
	 	By:	 /s/ Arthur S. Ainsberg
	 	 	Arthur S. Ainsberg

 

    9

     

    

 

	 	MEDLEY CAPITAL CORPORATION,
	 	a Delaware corporation
	 	 	 
	 	By:	/s/ Brook Taube
	 	Name:	Brook Taube
	 	Title:	Chief Executive Officer
	 	 	 
	 	MCC ADVISORS LLC,
	 	a Delaware limited liability company
	 	 	 
	 	By:	/s/ Richard T. Allorto, Jr.
	 	Name:	Richard T. Allorto, Jr.
	 	Title:	Chief Financial Officer
	 	 	 
	 	MEDLEY LLC,
	 	a Delaware limited liability company
	 	 	 
	 	By:	/s/ Brook Taube
	 	Name:	Brook Taube
	 	Title:	Co-Chief Executive Officer
	 	 	 
	 	MEDLEY GROUP LLC,
	 	a Delaware limited liability company
	 	 	 
	 	By:	/s/ Brook Taube
	 	Name:	Brook Taube
	 	Title:	Chief Executive Officer

 

    10

     

    

 

	 	FrontFour Master Fund, Ltd.
	 	 
	 	By:	FrontFour Capital Group LLC
	 	 	as Investment Manager
	 	 	 
	 	By:	/s/ David Lorber
	 	Name:	David Lorber
	 	Title:	Managing Member
	 	 	 
	 	FrontFour Capital Group LLC
	 	 	 
	 	By:	/s/ David Lorber
	 	Name:	David Lorber
	 	Title:	Managing Member

 

    11

     

    

 

Exhibit A

 

MDLY Acknowledgement and Agreement

 

Medley Management, Inc. (“MDLY”) acknowledges that
the Settlement Term Sheet, dated as of April 15, by and between the Plaintiffs and Defendants (the “Settlement Term Sheet”),
contemplates certain amendments to the MDLY Merger Agreement and the MCC Merger Agreement and certain other actions to be undertaken
by the parties thereto. Capitalized terms not defined herein used in this Exhibit A shall have the meanings set forth in
the Settlement Term Sheet.

 

In exchange and consideration for the release of MDLY by the
Plaintiffs and the Class in the Settlement Agreement, which will be in the form set forth in Section 3(d) of the Settlement
Term Sheet, MDLY hereby covenants and agrees to the following actions and undertakings:

 

		●	To participate and cooperate in the discussions and
efforts of Defendants to amend the MDLY Merger Agreement and the MCC Merger Agreement as contemplated in Section 2(a) of the Settlement
Term Sheet.

 

		●	To consent to the amendments to the MCC Merger Agreement
contemplated by Section 2(a)(i) of the Settlement Term Sheet, if and when presented to MDLY by SIC and MCC.

 

		●	To agree to the amendments to the MDLY Merger Agreement
and, if and when presented to MDLY by SIC and MCC, consent to the MCC Merger Agreement amendments contemplated by Sections
2(a)(ii) and (iii) of the Settlement Term Sheet.

 

		●	To work in good faith to agree to supplemental disclosures
relating to the MCC Merger and MDLY Merger consistent with the Delaware litigation, as contemplated by Section 2(b)(i)
of the Settlement Term Sheet.

 

		●	To waive and/or release any potential counterparty
of MCC from any applicable standstill or other agreements to which MDLY is a party that would inhibit or restrict the potential
counterparty’s participation in MCC’s exploration of strategic alternatives, as contemplated in Section 2(b)(ii)
of the Settlement Term Sheet.

 

		●	To agree to the definition of “Class”
in Section 3(c), and the Releases contemplated by Section 3(d) of the Settlement Term Sheet.

 

		●	To use reasonable efforts to obtain SEC exemptive
relief to allow for the consummation of the MCC Merger and the MDLY Merger consistent with Section 5 of the Settlement
Term Sheet.

 

For the avoidance of doubt, MDLY shall have no obligation to
agree or consent to, as applicable, (i) any modifications, amendments, waivers, or revisions to the terms of the MDLY Merger Agreement
or the MCC Merger Agreement except as set forth above with respect to the amendments contemplated by Section 2(a) of the Settlement
Term Sheet, or (ii) any other actions with respect to the Settlement Term Sheet.

 

	 	Medley Management Inc.
	 	 	 
	 	By:	/s/ Brook Taube
	 	 	Name: Brooke Taube
	 	 	Title: Chief Executive Officer

 

 

12Exhibit
4.28

 

 

THE SYMBOL
“[*]” INDICATES MATERIAL WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH
(i) NOT MATERIAL AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED.

 

 

 

 

 

 

RESEARCH
COLLABORATION 

 

AND

 

LICENSE AGREEMENT

 

by and
between

 

amgen
inc.

and

 

 

ENTERABIO
LTD.

 

 

 

 

Dated
as of December 10, 2018

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    

     

    

 

TABLE
OF CONTENTS

 

	Article
    1. DEFINITIONS	1
	Article
    2. Research Collaboration	10
	Article
    3. Preclinical Research & Development activities; Exclusivity	12
	Article
    4. LICENSE GRANT	15
	Article
    5. Regulatory Matters	17
	Article
    6. Development, manufacture and commercialization matters	17
	Article
    7. FEES, ROYALTIES, & PAYMENTS	18
	Article
    8. Intellectual property	25
	Article
    9. REPRESENTATIONS, WARRANTIES AND COVENANTS	28
	Article
    10. INDEMNIFICATION	33
	Article
    11. limitations of liability	34
	Article
    12. CONFIDENTIALITY	34
	Article
    13. TERM & TERMINATION	37
	Article
    14. MISCELLANEOUS	39

 

 

EXHIBITS

EXHIBIT A – PRESS RELEASE

 

    2

     

    

 

RESEARCH
COLLABORATION AND LICENSE AGREEMENT

 

This
Research Collaboration and License Agreement (“Agreement”) is entered into as of December 10, 2018 (the “Effective
Date”) by and between Amgen Inc., a Delaware corporation having an address at One Amgen Center Drive, Thousand Oaks,
California 91320, USA (“Amgen”) and EnteraBio Ltd., an Israeli company having an address at Minrav Building,
5th Floor, PO Box 12117, Jerusalem 91220, Israel (“EnteraBio”). Amgen and EnteraBio are each hereafter referred
to individually as a “Party” and together as the “Parties”.

 

WHEREAS,
Amgen has research, development, manufacturing and commercialization expertise for the development and commercialization of pharmaceutical
and biologics products;

 

WHEREAS,
EnteraBio has technology and expertise relating to oral drug delivery of large molecule products;

 

WHEREAS,
Amgen and EnteraBio desire to collaborate in the performance of a preclinical research and development program for purposes of
the discovery of clinical candidates from the Collaboration Programs (as defined below); and

 

NOW,
THEREFORE, in consideration of the mutual covenants contained herein, and for other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:

 

Article
1. DEFINITIONS

 

All
references to particular Exhibits, Articles or Sections mean the Exhibits to, and Articles and Sections of, this Agreement, unless
otherwise specified. For the purposes of this Agreement and the Exhibits and Appendices hereto, the following words and phrases
have the following meanings:

 

Section
1.1 “Abandoned Patent Right” has the meaning set forth in Section 8.2.3.

 

Section
1.2 “Affiliate” means, with respect to any Person, any other Person that controls, is controlled by or
is under common control with such Person, for as long as such control exists. For purposes of this Section, “control”
means the direct or indirect ownership of more than fifty percent (50%) (or, if local law restricts foreign ownership, of the
maximum ownership percentage that may, under such local law, be owned by foreign interests) of the voting or economic interest
of a Person, or the power, whether pursuant to contract, ownership of securities or otherwise, to direct the management and policies
of a Person. For clarity, once a Person ceases to be an Affiliate of a Party, then, without any further action, such Person shall
cease to have any rights, including license and sublicense rights, under this Agreement by reason of being an Affiliate of such
Party.

 

Section
1.3 “Agreement” has the meaning set forth in the Preamble.

 

Section
1.4 “Amgen” has the meaning set forth in the Preamble.

 

Section
1.5 “Amgen Acquiree” has the meaning set forth in Section 14.9.

 

Section
1.6 “Amgen Acquisition” has the meaning set forth in Section 14.9.

 

Section
1.7 “Amgen Indemnified Parties” has the meaning set forth in Section 10.1.1.

 

    -1-

     

    

 

Section
1.8 “Amgen IP” means [*].

 

Section
1.9  “Amgen Licensed Know-How” means [*].

 

Section
1.10 “Amgen Patents” means [*].

 

Section
1.11  “Anti-Bribery and Anti-Corruption Laws” has the meaning set forth in Section 9.4(c)(i)(b).

 

Section
1.12 “Anti-Corruption Policies” has the meaning set forth in Section 9.4(c)(i)(a).

 

Section
1.13 “Background IP” means Patent Rights and Know-How (a) Controlled by a Party prior to the Effective
Date or (b) Controlled by such Party during the Term, but not generated in the performance of the activities contemplated under
this Agreement.

 

Section
1.14 “Blocking Patents” means as to a Product, in the case of Amgen, any Patent Rights Controlled by a
Third Party that claim, in a particular country, the composition of matter or method of use of such Product, and which such Patent
Rights would be infringed by the manufacture, use, offer for sale, sale, import, or export of such Product in such country.

 

Section
1.15  “Change of Control” means (a) the closing of the sale, transfer, exclusive license or other disposition
of all or substantially all of EnteraBio’s assets or intellectual property, (b) the consummation of the merger or consolidation
of EnteraBio with or into another entity (except a merger or consolidation in which the holders of capital stock of EnteraBio
immediately prior to such merger or consolidation continue to hold more than 50% of the voting power of the capital stock of EnteraBio
or the surviving or acquiring entity), (c) the closing of the transfer (whether by merger, consolidation or otherwise), in one
transaction or a series of related transactions, to a person or group of affiliated persons (other than an underwriter of EnteraBio’s
securities), of EnteraBio’s securities if, after such closing, such person or group of affiliated persons would hold 50%
or more of the outstanding voting stock of EnteraBio (or the surviving or acquiring entity) or (d) a liquidation, dissolution
or winding up of EnteraBio.

 

Section
1.16 “Collaboration IP” means [*].

 

Section
1.17 “Collaboration Know-How” means [*].

 

Section
1.18 “Collaboration Patents” means [*].

 

Section
1.19 “Collaboration Program(s)” [*].

 

Section
1.20 “Combination Product” has the meaning set forth in Section 1.67.

 

    -2-

     

    

 

Section
1.21 “Commercially Reasonable Efforts” means, with respect to a Party, [*].

 

Section
1.22 “Confidential Disclosure Agreement” means that certain Confidential Disclosure Agreement entered into
between the Parties as of May 5, 2017, as amended.

 

Section
1.23 “Confidential Information” has the meaning set forth in Section 12.1.1.

 

Section
1.24 “Control” or “Controlled” means, with respect to any Know-How, Patent Right, or
other intellectual property right, the possession (whether by ownership or license) by a Party or its Affiliate of the ability
to grant to the other Party a license or access as provided herein to such Know-How, Patent Right, or other intellectual property
right, without violating the terms of any agreement or other arrangement with any Third Party, or being obligated to pay any royalties
or other consideration therefor, in existence as of the time such Party or its Affiliates would first be required hereunder to
grant the other Party such license or access; [*].

 

Section
1.25 “Cover” means, with respect to an issued and unexpired claim of a Patent Right and a product, such
claim would (absent a license thereunder or ownership thereof) be Infringed by the Exploitation of such product, and with respect
to a Patent Right which is a pending application of a patent, the application shall be treated as if issued in the form then currently
being prosecuted. Cognates of the word “Cover” have correlative meanings.

 

Section
1.26 “Defending Party” has the meaning set forth in Section 8.4.

 

Section
1.27 “Derivatives” has the meaning set forth in Section 8.1.3.

 

Section
1.28 “Disclosing Party” has the meaning set forth in Section 12.1.1.

 

Section
1.29 “EMA” means the European Medicines Agency or any successor entity thereto.

 

Section
1.30 “Enforcing Party” has the meaning set forth in Section 8.5.3.

 

Section
1.31 “EnteraBio” has the meaning set forth in the Preamble.

 

Section
1.32 “EnteraBio Acquiree” has the meaning set forth in Section 14.10.

 

Section
1.33 “EnteraBio Acquisition” has the meaning set forth in Section 14.10.

 

Section
1.34 “EnteraBio IP” means [*].

 

    -3-

     

    

 

Section
1.35  “EnteraBio Indemnified Parties” has the meaning set forth in Section 10.1.2.

 

Section
1.36 “EnteraBio Licensed Know-How” means [*].

 

Section
1.37 “EnteraBio Patents” means [*].

 

Section
1.38  “EnteraBio Platform” means the technology platform as agreed upon in writing by the Parties.

 

Section
1.39 “E.U.” means those countries, nations, states or other territories under the jurisdiction of the EMA,
as such jurisdiction may change from time to time.

 

Section
1.40 “Executive Officers” means (a) with respect to EnteraBio, the Chief Executive Officer, and (b) with
respect to Amgen, a Vice President, or in the case of both parties, any other person that such officer designates, who has the
authority to make decisions on behalf of such respective company, from time to time.

 

Section
1.41 “Exploit” means to discover, research, develop, make, have made, use, offer for sale, sell, have sold,
import, export, or otherwise exploit, or transfer possession of or title in. Cognates of the word “Exploit”
shall have correlative meanings.

 

Section
1.42 “FDA” means the United States Food and Drug Administration or any successor entity thereto.

 

Section
1.43 “First Commercial Sale” means, [*].

 

Section
1.44 “First Year” has the meaning set forth in Section 7.1.2(a).

 

Section
1.45 “First Year FTE Payment” has the meaning set forth in Section 7.1.2(a).

 

Section
1.46 “GAAP” means the then current generally accepted accounting principles in the United States as established
by the Financial Accounting Standards Board or any successor entity or other entity generally recognized as having the right to
establish such principles in the United States, in each case consistently applied.

 

Section
1.47 “Generic Version” means, with respect to a Product, any pharmaceutical product that (a) is sold
by a Third Party that is not a licensee or sublicensee of Amgen or its Affiliates, or any of their licensees or sublicensees;
(b) contains the same active pharmaceutical ingredient as such Product; and (c) is approved in reliance, in whole or
in part, on the prior approval (or on safety or efficacy data submitted in support of the prior approval) of such Product as determined
by the applicable Regulatory Authority, including any product authorized for sale (i) in the U.S. pursuant to Section 505(b)(2)
or Section 505(j) of the FD&C Act (21 U.S.C. 355(b)(2) and 21 U.S.C. 355(j), respectively), (ii) in the E.U. pursuant
to a provision of Articles 10, 10a or 10b of Parliament and Council Directive 2001/83/EC as amended (including an application
under Article 6.1 of Parliament and Council Regulation (EC) No 726/2004 that relies for its content on any such provision), or
(iii) in any other country or jurisdiction pursuant to any equivalent of such provisions.

 

    -4-

     

    

 

Section
1.48  “GLP Toxicology Study” means a toxicology study that meet the requirements set forth in 21 CFR Part
58 pertaining to good laboratory practice for use or intended for use in an IND and are required to be included in the filing
of an IND, but excluding any toxicology study performed in the course of evaluating compounds prior to selection of a development
candidate by the JRC.

 

Section
1.49 “GMP” or “Good Manufacturing Practices” means the then-current Good Manufacturing
Practices required by the FDA, as set forth in the U.S. Food, Drug and Cosmetic Act and the regulations promulgated thereunder,
for the manufacture and testing of pharmaceutical materials, and comparable laws or regulations applicable to the manufacture
and testing of pharmaceutical materials promulgated by other Regulatory Authorities, as they may be updated from time to time.

 

Section
1.50 “Governmental Authority” means any court, agency, department, authority or other instrumentality of
any national, state, county, city or other political subdivision.

 

Section
1.51 “Improvement” means an advancement, modification, development or improvement.

 

Section
1.52 “IND” means, with respect to the United States, an investigational new drug application as defined
in applicable regulations promulgated by the FDA and filed with the FDA for human clinical testing of a drug or, with respect
to any jurisdiction other than the United States, an equivalent filing thereof.

 

Section
1.53 “Indemnitee” has the meaning set forth in Section 10.1.3.

 

Section
1.54 “Indemnitor” has the meaning set forth in Section 10.1.3.

 

Section
1.55 “Initial Program” means the initial Collaboration Program as agreed upon in writing by the Parties.

 

Section
1.56 “Initiation” means, [*]. Cognates of the word “Initiation” have correlative meanings.

 

Section
1.57 “Issuing Party” has the meaning set forth in Section 12.2.2.

 

Section
1.58 “Joint Research Committee” or “JRC” has the meaning set forth in Section 2.1.1.

 

Section
1.59 “Know-How” means proprietary techniques, technology, trade secrets, inventions (whether patentable
or not), methods, know-how, data and results (including pharmacological, toxicological and clinical data and results), analytical
and quality control data and results, regulatory documents, and other information, compositions of matter, cells, cell lines,
assays, animal models, reagents and other physical, biological, or chemical material.

 

Section
1.60 “Law” means, individually and collectively, any and all laws, ordinances, rules, directives, administrative
circulars and regulations of any kind whatsoever of any Governmental Authority within the applicable jurisdiction.

 

    -5-

     

    

 

Section
1.61  “Licensed Field” means [*].

 

Section
1.62 “Losses” has the meaning set forth in Section 10.1.1.

 

Section
1.63 “Marketing Approval” means all approvals, licenses, registrations or authorizations of the Regulatory
Authority in a country, necessary for the manufacture, use, storage, import, marketing and sale (including with respect to pricing
and reimbursement) of a Product in such country.

 

Section
1.64 “Material Anti-Corruption Law Violation” means a violation of any Anti-Bribery and Anti-Corruption
Laws relating to the subject matter of this Agreement which would, if it were publicly known, in the reasonable view of a Party,
have a material adverse effect on it or its reputation because of its relationship with the other Party.

 

Section
1.65 “Milestone Events” has the meaning set forth in Section 7.2.1.

 

Section
1.66 “Milestone Payments” has the meaning set forth in Section 7.2.1.

 

Section
1.67 “Net Sales” means, with respect to a certain time period and Product, [*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

    -6-

     

    

 

[*].

 

Section
1.68 “Non-Publishing Party” has the meaning set forth in Section 12.3.

 

Section
1.69 “Party” and “Parties” has the meaning set forth in the Preamble.

 

Section
1.70 “Patent Rights” means (a) all patents, priority patent filings and patent applications, and (b) any
renewal, divisional, continuation (in whole or in part), or request for continued examination of any of such patents, and patent
applications, and any and all patents or certificates of invention issuing thereon, and any and all reissues, reviews, reexaminations,
extensions, divisions, renewals, substitutions, confirmations, registrations, revalidations, revisions, and additions of or to
any of the foregoing.

 

    -7-

     

    

 

Section
1.71 “Person” means any corporation, limited or general partnership, limited liability company, joint venture,
trust, unincorporated association, governmental body, authority, bureau or agency, any other entity or body, or an individual.

 

Section
1.72 “Phase 1 Clinical Trial” means any first in human clinical trial of a Product conducted mainly
to evaluate the safety of chemical or biologic agents or other types of inventions (e.g., a new radiation therapy technique) that
would satisfy the requirements of 21 CFR § 312.21(a) or its non-U.S. equivalents.

 

Section
1.73 “Phase 2 Clinical Trial” means any human clinical trial of a Product conducted mainly to test
the effectiveness of chemical or biologic agents or other types of interventions for purposes of identifying the appropriate dose
for a Phase 3 Clinical Trial for a particular indication or indications that would satisfy the requirements of 21 CFR § 312.21(b)
or its non-United States equivalents. A “Phase 2/3 Clinical Trial” shall be deemed to be a Phase 2 Clinical
Trial with respect to the portion of that clinical trial that is regarded as its Phase 2 component, in accordance with the applicable
protocol.

 

Section
1.74 “Phase 3 Clinical Trial” means any human clinical trial of a Product designed to: (a) establish
that such Product is safe and efficacious for its intended use; (b) define warnings, precautions and adverse reactions that are
associated with the Product in the dosage range to be prescribed; and (c) support regulatory approval of such Product, that would
satisfy the requirements of 21 CFR § 312.21(c) or its non-U.S. equivalents. A “Phase 2/3 Clinical Trial”
shall be deemed to be a Phase 3 Clinical Trial with respect to the portion of that clinical trial that is regarded as its Phase
3 component, in accordance with the applicable protocol.

 

Section
1.75 “Preclinical Research & Development” means, with respect to a particular Collaboration Program,
any discovery, research, design, preclinical and process development activities relating to such Collaboration Program, as set
forth in the applicable Work Plan.

 

Section
1.76 “Preclinical R&D Term” means, [*].

 

Section
1.77 “Product” means a pharmaceutical or biologic product [*].

 

Section
1.78 “Public Official or Entity” means (a) any officer, employee (including physicians, hospital administrators,
or other healthcare professionals), agent, representative, department, agency, de facto official, representative, corporate entity,
instrumentality or subdivision of any government, military or international organization, including any ministry or department
of health or any state-owned or affiliated company or hospital, or (b) any candidate for political office, any political party
or any official of a political party.

 

Section
1.79 “Publishing Party” has the meaning set forth in Section 12.3.

 

Section
1.80 “Receiving Party” has the meaning set forth in Section 12.1.1.

 

    -8-

     

    

 

Section
1.81 Regulatory Authority” means any Governmental Authority or other authority responsible for granting Marketing Approvals
for Products, including the FDA, EMA and any corresponding national or regional regulatory authorities.

 

Section
1.82 “Regulatory Filing” means any filing with any Governmental Authority with respect to the research,
development, manufacture, distribution, pricing, reimbursement, marketing or sale of a Product.

 

Section
1.83 “Release” has the meaning set forth in Section 12.2.2.

 

Section
1.84 “Reviewing Party” has the meaning set forth in Section 12.2.2.

 

Section
1.85 “Royalty Term” has the meaning set forth in Section 7.5.2.

 

Section
1.86 “Sale Transaction” has the meaning set forth in Section 14.8.

 

Section
1.87 “Second Year” has the meaning set forth in Section 7.1.2(b).

 

Section
1.88 “Second Year FTE Payment” has the meaning set forth in Section 7.1.2(b).

 

Section
1.89 “Second Year Prepayment Amount” has the meaning set forth in Section 7.1.2(f).

 

.

 

Section
1.90 “Selling Party” has the meaning set forth in Section 1.90.

 

Section
1.91 “Sublicensee(s)” means shall mean any Third Party to which a Party has granted a sublicense under
this Agreement.

 

Section
1.92 “Termination Party” means (a) Amgen, in the case of termination by (i) Amgen pursuant to Sections
13.3.1, 13.3.2 or (ii) EnteraBio pursuant to Section 13.2.1, and (b) EnteraBio, in the case of termination by Amgen pursuant to
Section 13.3.1.

 

Section
1.93 “Term” has the meaning set forth in Section 13.1.

 

Section
1.94 “Territory” means the entire world.

 

Section
1.95 “Third Party” means a Person other than (a) Amgen or any of its Affiliates and (b) EnteraBio or any
of its Affiliates.

 

Section
1.96 “Third Party Acquirer” has the meaning set forth in Section 14.9.

 

Section
1.97 “Third Party Claim” has the meaning set forth in Section 10.1.1.

 

Section
1.98 “U.S.” means the United States of America and its territories and possessions.

 

Section
1.99 “Valid Claim” means a claim in an issued and unexpired Patent Right that has not been disclaimed,
revoked, held unenforceable, unpatentable or invalid by a decision of a court or other governmental agency of competent jurisdiction,
unappealable or unappealed within the time allowed for appeal, and that has not been admitted to be invalid or unenforceable through
re-examination, re-issue, disclaimer or otherwise, or lost in an interference proceeding; [*].

 

Section
1.100 “VAT” has the meaning set forth in Section 7.11.2.

 

    -9-

     

    

 

Section
1.101 “Work Plan” means, for each Collaboration Program, the comprehensive plan, setting forth the research
strategy, activities and deliverables for the Preclinical Research & Development of Products under the applicable Collaboration
Program, which shall be agreed upon in writing by the Parties.

 

Article
2. Research Collaboration

 

Section
2.1 Management.

 

2.1.1       
Overview. Within thirty (30) days after the Effective Date, the Parties shall establish a joint research committee
(the “Joint Research Committee” or the “JRC”) which shall manage the progress and direction
of Preclinical Research & Development collaboration between the Parties.

 

2.1.2       
Joint Research Committee.

 

(a)                    
Composition. The Joint Research Committee shall be comprised of three (3) named representatives of each Party
(or such other number as the Parties may agree). The JRC will be led by two (2) co-chairs, one (1) appointed by each Party. Within
thirty (30) days after the Effective Date, each Party shall designate by written notice to the other Party its initial representatives
on the JRC. Each Party may replace one or more of its representatives, in its sole discretion, effective upon written notice to
the other Party of such change. 

 

(b)                    
Function and Powers of the JRC. The JRC shall, consistent with the terms and conditions set forth in this
Agreement: 

 

		(i)	amend
                                         a Work Plan, provided that the JRC shall have no authority, without the express written
                                         consent of both Parties, to amend a Work Plan in a manner that would require a Party
                                         to incur aggregate expenses that are higher than those contemplated by the previously
                                         agreed upon Work Plan;

 

		(ii)	review
                                         progress of the Preclinical Research & Development against the goals and/or deliverables
                                         set forth in a Work Plan;

 

		(iii)	extend
                                         the Preclinical R&D Term for one or more Collaboration Programs;

 

		(iv)	identify
                                         Product development candidates, subject to the procedure in Section 3.6 for selecting
                                         Post-Effective Date Programs, provided however that Amgen shall have the right to elect,
                                         in its sole discretion, whether to Initiate a GLP Toxicology Study of a Product pursuant
                                         to Section 4.5.1; establish subcommittees, as appropriate, as described more fully in
                                         Section 2.1.2(d) below;

 

		(v)	direct
                                         and oversee any subcommittee;

 

		(vi)	approve
                                         annual Out-of-Pocket Expense budget, in accordance with Section 3.1;

 

		(vii)	resolve
                                         disputed matters that may arise at any subcommittee; and

 

    -10-

     

    

 

		(viii)	perform
                                         any and all tasks and responsibilities that are expressly attributed to the JRC under
                                         this Agreement.

 

Subject
to Section 14.12, the JRC shall have the foregoing authority on a Collaboration Program-by-Collaboration Program basis only during
the applicable Preclinical R&D Term. The JRC shall only have such powers as are specifically assigned to it in this Agreement,
and such powers shall be subject to the terms and conditions set forth in this Agreement. Without limiting the generality of the
foregoing, the JRC shall have no power to amend or modify this Agreement or to amend, modify or waive compliance with the terms
of this Agreement, and no decision of the JRC shall be in contravention of any terms and conditions of this Agreement.

 

(c)              
Meetings. The Joint Research Committee shall meet at least twice per year or more or less often as otherwise
agreed by the Parties, and such meetings may be conducted by telephone, videoconference or in person as determined by the co-chairs.
As appropriate, and provided that not less than two (2) business days’ prior written notice has been given to the other
Party, other employees of the Parties may attend Joint Research Committee meetings as observers, but a Party shall not bring a
Third Party to a meeting without the other Party’s prior consent, which consent shall not be unreasonably withheld. Each
Party may also call for special meetings of the Joint Research Committee with reasonable prior written notice to the other Party
(it being agreed that at least ten (10) business days shall constitute reasonable notice) to resolve particular matters requested
by such Party and within the decision-making responsibility of the Joint Research Committee. Minutes will be kept of all JRC meetings
and will reflect material decisions made at such meetings. Meeting minutes will be prepared by the Parties on a rotating basis
and sent to each member of the JRC for review and approval promptly following each meeting. Minutes will be deemed approved unless
a member of the JRC objects to the accuracy of such minutes within thirty (30) days of receipt. Each Party shall be responsible
for all of its own expenses incurred in connection with participating in all such meetings.

 

(d)              
Subcommittees. The JRC may establish and disband subcommittees as deemed necessary by the JRC. Each such
subcommittee shall consist of the same number of representatives designated by each Party, which number shall be mutually agreed
by the Parties. Each Party shall be free to change its representatives on written notice to the other Party or to send a substitute
representative to any subcommittee meeting. Each Party’s representatives and any substitute for a representative shall be
bound by the obligations of confidentiality set forth in Article 12. Except as expressly provided in this Agreement, no subcommittee
shall have the authority to bind the Parties hereunder and each subcommittee shall report to the JRC. Each Party shall be responsible
for all of its own expenses incurred in connection with participating in all such meetings.

 

2.1.3       
Cooperation. Each Party shall provide the JRC such information as reasonably required under any Work Plan, or
as reasonably requested by the other Party and reasonably available, relating to the progress of the goals or performance of activities
under such Work Plan.

 

2.1.4       
Decisions. Other than as expressly set forth herein, in order to make any decision required of it hereunder,
the JRC must have present (in person, by videoconference or telephonically) at least the co-chair of each Party (or his/her designee
for such meeting). Decisions of the JRC shall be by consensus, with each Party having one (1) vote. If the JRC cannot reach consensus
or a dispute arises, in each case, that cannot be resolved in good faith discussions of the JRC for a period of at least sixty
(60) days (whether the matter originated at the JRC or within a subcommittee), the co-chair of either Party may

 

    -11-

     

    

 

cause
such dispute to be referred to the Executive Officers for resolution, [*].

 

2.1.5       
Discontinuation of JRC. Subject to Section 14.12, the JRC shall continue to exist and execute its functions
and powers set forth herein until the expiration of the last Preclinical R&D Term.

 

Article
3. Preclinical Research & Development activities; Exclusivity

 

Section
3.1 Preclinical Research & Development of Products.

 

3.1.1       
Within thirty (30) days of the Effective Date, each Party shall commence Preclinical Research & Development activities
assigned to it under the Work Plan for the Initial Collaboration Program. During the Preclinical R&D Term of any Collaboration
Program, each Party shall use its Commercially Reasonable Efforts to conduct its Preclinical Research & Development activities
of the Products in accordance with the applicable Work Plan. In performing its activities under each Work Plan, each Party shall
(and shall cause its Affiliates and Third Party subcontractors, as applicable, to) perform such activities in compliance with
all applicable scientific standards, laboratory practices and all applicable Laws, and engage and appropriately control adequately
qualified personnel.

 

3.1.2       
The Parties agree that Amgen shall prepay or reimburse EnteraBio for its costs (i.e., internal and out-of-pocket expenses,
including costs of shipping Materials, as described in Section 3.5) with respect to the Preclinical Research & Development
activities EnteraBio conducts (including through its Affiliates or Third Party contractors) under each Work Plan (collectively,
“Preclinical Research & Development Costs”) as set forth in this Section 3.1.2, which, for clarity, subject
to the first sentence of Section 3.1.2(a), shall be in addition to the payments to EnteraBio contemplated in Sections 3.7 (Extension
of Preclinical R&D Term), 7.1.1 (Technology Access Payment; Upfront Payment), 7.2 (Milestone Payments) and 7.3 (Royalties).

 

(a)              
Internal Preclinical Research & Development Costs. The Parties agree that, unless otherwise agreed in writing,
the Amgen payments to EnteraBio contemplated in Section 7.1.1 (Technology Access Payment; Upfront Payment) and 7.1.2 (R&D
Costs) shall cover EnteraBio’s internal Preclinical Research and Development Costs for the first two years of each Collaboration
Program. [*]. 

 

    -12-

     

    

 

(b)              
Out-of-Pocket Preclinical Research & Development Costs. On an annual basis, the JSC shall discuss in good faith
and approve an annual budget for EnteraBio out-of-pocket Preclinical Research and Development Costs for each Collaboration Program
(each, an “Annual Out-of-Pocket Budget”), which shall include an agreed-upon timeline for any Amgen prepayment
of anticipated out-of-pocket Preclinical Research & Development Costs. Unless otherwise agreed to by the Parties in writing,
following approval of the EnteraBio Out-of-Pocket Budget, Amgen shall prepay and/or reimburse, as applicable, EnteraBio’s
reasonably documented out-of-pocket Preclinical Research & Development Costs in accordance with the Annual Out-of-Pocket Budget.
In the event that Amgen prepays an amount of out-of-pocket Preclinical Research and Development Costs and such amount of such
costs were not incurred by EnteraBio during such year, then, at Amgen’s option, EnteraBio shall either promptly refund to
Amgen the remaining prepayment amount or apply such amount against the following year’s out-of-pocket Preclinical Research
and Development Costs. 

 

(c)              
No Obligation to Incur Preclinical Research & Development Costs. Notwithstanding anything in this Agreement
to the contrary, EnteraBio shall have no obligation to conduct (or engage any Affiliate or Third Party subcontractor to conduct)
any Preclinical Research & Development activity if the Parties have not agreed on Amgen’s reimbursement of the EnteraBio
internal and out-of-pocket Preclinical Research & Development Costs incurred in connection with such activity pursuant to
Section 3.1.2(a) and/or (b).

 

Section
3.2 Subcontracting. Each Party may engage its Affiliates, or Third Party subcontractors (including contract research
organizations and contract manufacturing organizations) to perform certain of its obligations under this Agreement; [*]. Any Third
Party subcontractor to be engaged by a Party to perform such Party’s obligations set forth in this Agreement will meet the
qualifications typically required by such Party for the performance of work similar in scope and complexity to the subcontracted
activity. The activities of any such Third Party subcontractors will be considered activities of such subcontracting Party under
this Agreement. The subcontracting Party will be responsible for ensuring compliance by any such Third Party subcontractors with
the terms of this Agreement, as if such Third Party(ies) are such Party hereunder. Each subcontracting Party will, and will contractually
require that its Affiliates and subcontractors, if any, conduct the relevant Preclinical Research & Development activities
in accordance with such subcontracting Party’s commitments with respect to the applicable Work Plan.

 

Section
3.3 Data. EnteraBio shall, at Amgen’s written request, promptly make available to Amgen all data generated by
or on behalf of EnteraBio and/or its Affiliates that is related to any and all Collaboration Programs and/or Products during the
applicable Preclinical R&D Term. Amgen shall, at EnteraBio’s written request, promptly make available to EnteraBio all
data generated by or on behalf of Amgen and/or its Affiliates that is reasonably necessary by EnteraBio to conduct its activities
contemplated under the applicable Work Plan during the applicable Preclinical R&D Term and to carry out its obligations and
exercise its rights under this Agreement.

 

    -13-

     

    

 

Section
3.4 Exclusivity.

 

3.4.1       
[*]. 

 

Section
3.5 Material Transfer. To facilitate the Preclinical Research & Development, either Party may provide to the other
Party certain biological materials or chemical compounds, owned by or licensed to the supplying Party for use by the other Party
in furtherance of Preclinical Research & Development (such materials or compounds provided hereunder are referred to, collectively,
as “Materials”). Except as otherwise expressly provided under this Agreement, all such Materials delivered
to the other Party shall remain the sole property of the supplying Party, shall be used only in furtherance of the exercise of
rights or performance of obligations under this Agreement and in accordance with this Agreement and solely under the control of
the other Party, shall not be used or delivered to or for the benefit of any Third Party without the prior written consent of
the supplying Party, and shall not be used in research or testing involving human subjects or in animals intended for food use,
in each case unless otherwise specifically contemplated hereunder), and will be used in compliance with all applicable Law. The
provision of Materials to the receiving Party hereunder does not grant such Party any rights other than those specifically granted
in this Agreement. Delivery of the Materials shall be EXW Incoterms 2010 (the supplying Party’s facilities). The receiving
Party shall bear all responsibility for the shipped Materials thereafter, provided however, that Amgen shall bear the entire costs
of transferring the Materials to EnteraBio and the insurance costs, to the extent applicable. The receiving Party shall be responsible
for any and all consents, approvals, authorizations or other permits necessary for the use, handling, transfer, and/or storage
of the Materials. The receiving Party shall: (a) receive the Materials; (b) promptly notify the supplying Party when the Materials
have been received; and (c) forward to the supplying Party any applicable chain of custody forms, in-transport temperature record(s)
and receipt verification documentation and such other documentation reasonably requested by the supplying Party. The receiving
Party shall be responsible for import clearance (including preparing any necessary documentation with respect thereto) and making
entry of shipment. The supplying Party shall provide the relevant shipping documentation, pro forma invoice and airway bill, together
with such other documentation necessary for the use, handling, transfer, and/or storage of the Materials. The Materials supplied
under this Section 3.5 are supplied “as is” and must be used with prudence and appropriate caution in any experimental
work, since not all of their characteristics may be known. Except as expressly set forth herein, THE MATERIALS ARE WITHOUT ANY
REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR OF FITNESS FOR ANY PARTICULAR
PURPOSE OR ANY WARRANTY THAT THE USE OF THE MATERIALS WILL NOT INFRINGE OR VIOLATE ANY PATENT OR OTHER PROPRIETARY RIGHTS OF ANY
THIRD PARTY. During the Preclinical R&D Term for any Collaboration Program, for record-keeping purposes, the Parties shall
compile a list (that shall include the type of material, quantity, shipping date and any other relevant details) on a quarterly
basis setting forth the Materials provided to/from each Party, which document shall be signed by an authorized representative
of each Party. For clarity, this Section 3.5 shall apply during the applicable Preclinical R&D Term only, after which the
Parties will enter into an appropriate material transfer agreement with respect to any transfer of Materials, which agreement
will be subject to this Agreement and will be interpreted consistent with the terms hereof.

 

    -14-

     

    

 

Section
3.6 Post-Effective Date Programs. At any time within the [*] period following the Effective Date, Amgen shall have
the right to select up to two (2) additional Collaboration Programs (each, a “Post-Effective Date Program”).
During such aforementioned [*] period, Amgen may propose by written notice to EnteraBio any Post-Effective Date Program. Upon
EnteraBio’s receipt of any proposed Post-Effective Date Program, the Parties shall discuss in good faith the proposed program
and negotiate a reasonable Work Plan related thereto. [*]. In the event that Amgen proposes any Post-Effective Date Program(s)
within the applicable [*] period and the Parties are ultimately unable to agree on any such Post-Effective Date Program or the
Work Plan related thereto, Amgen shall be entitled to propose alternative Post-Effective Date Program(s) in place of the earlier
proposed program(s) to which the Parties are unable to agree during such [*] period.

 

Section
3.7 Extension of Preclinical R&D Term. [*].

 

Section
3.8 [*].

 

    -15-

     

    

 

Article
4. LICENSE GRANT

 

Section
4.1 License Grant.

 

4.1.1       
Preclinical License. During the Preclinical R&D Term for each Collaboration Program, EnteraBio hereby grants
to Amgen a non-exclusive, worldwide, royalty-free right under EnteraBio IP solely to conduct Preclinical Research & Development
as contemplated to be performed by Amgen under each Work Plan. During the Preclinical R&D Term for each Collaboration Program,
Amgen hereby grants to EnteraBio a non-exclusive, worldwide, royalty-free right under Amgen IP solely to conduct Preclinical Research
& Development as contemplated to be performed by EnteraBio under each Work Plan.

 

4.1.2       
License Grant to Amgen. Subject to the terms and conditions of this Agreement, EnteraBio hereby grants to Amgen
an exclusive (even as to EnteraBio and its Affiliates, except as expressly set forth herein and subject to EnteraBio and its Affiliates
retaining the non-exclusive rights reasonably necessary or useful to perform EnteraBio’s obligations under each Work Plan),
royalty-bearing, sublicenseable (but only in accordance with Section 4.2), license under EnteraBio IP to Exploit Products in the
Licensed Field in the Territory during the Term.

 

Section
4.2 Sublicenses. Amgen and its Affiliates shall be entitled, without the prior consent of EnteraBio, to grant one or
more sublicenses under the licenses granted to Amgen under Section 4.1, in full or in part, by means of written agreement to Third
Parties (with the right to sublicense through multiple tiers); provided, however, that as a condition precedent to and
requirement of any such sublicense: (a) any such permitted sublicense shall be consistent with and subject to the terms and
conditions of this Agreement; and (b) Amgen will continue to be responsible for full performance of Amgen’s obligations
under this Agreement and will be responsible for all actions of such Sublicensee as if such Sublicensee were Amgen hereunder.

 

Section
4.3 Transfer of Know-How. Amgen shall transfer to EnteraBio the Amgen Licensed Know-How contemplated to be so transferred
as set forth in the applicable Work Plan. EnteraBio shall transfer to Amgen the EnteraBio Licensed Know-How contemplated to be
so transferred as set forth in the applicable Work Plan.

 

Section
4.4 No Other Rights. No right or license under any Patent Rights or other intellectual property rights of a Party is
granted or shall be granted by implication to the other Party, and each Party covenants not to practice or use any Patent Rights
or other intellectual property rights of the other Party except pursuant to the licenses expressly granted in this Agreement or
any other written agreement between the Parties. All such rights or licenses are or shall be granted only as expressly provided
in the terms of this Agreement.

 

    -16-

     

    

 

Section
4.5 Initiation of a GLP Toxicology Study.

 

4.5.1       
[*]. 

 

4.5.2       
[*] 

 

Article
5. Regulatory Matters

 

Section
5.1 Amgen Responsibilities. Except as expressly provided in the Work Plans, Amgen will be solely responsible for the
preparation, submission and maintenance of all Regulatory Filings and obtaining all Marketing Approvals with respect to Products.
EnteraBio will reasonably cooperate with Amgen, at Amgen’s reasonable request and expense, with respect to any regulatory
matters related to Products. Amgen will own all right, title and interest in and to any and all Regulatory Filings and Marketing
Approvals and all such Regulatory Filings and Marketing Approvals will be held in the name of Amgen or its designee, and EnteraBio
will execute all documents and take all actions as are reasonably requested by Amgen to vest such title in Amgen or such designee,
as applicable.

 

Section
5.2 Regulatory Updates. Amgen shall keep EnteraBio reasonably informed of all material regulatory developments relating
to Products in the Territory through the annual development reports under Section 6.3 or as otherwise reasonably requested by
EnteraBio from time to time.

 

Article
6. Development, manufacture and commercialization matters

 

Section
6.1 General.

 

6.1.1       
Products. Following the Effective Date and at all times during the Term, except as otherwise expressly set forth
herein, Amgen shall be responsible for, and shall bear all costs associated with, the research, development, manufacture and commercialization
of Products, including development, distribution, marketing and sales activities. For clarity, after completion of the applicable
Work Plan, Amgen shall continue to have the right to conduct Preclinical Research & Development with respect to the applicable
Products. Subject to the express written terms of this Agreement, all decisions concerning the discovery, research, development,
marketing and sales of Products including the clinical and regulatory strategy, design, sale, price and promotion of Products
covered under this Agreement shall be within the sole discretion of Amgen. Upon [*] EnteraBio will transfer (subject to the license
grant in Section 4.1.2) to Amgen all EnteraBio Licensed Know-How, at Amgen’s costs and expense, as is reasonably necessary
for Amgen to manufacture, develop and seek Marketing Approval for the applicable Products, including all materials for supporting
regulatory filings consistent with Amgen’s obligations under Article 5. Amgen understands and acknowledges that EnteraBio
Licensed Know-how constitutes highly sensitive and Confidential Information of EnteraBio and prior to any transfer to any Third
Party, Amgen will notify EnteraBio to discuss the proposed transfer to ensure the reasonable safeguards are in place with regard
to maintaining the confidentiality of EnteraBio Licensed Know-How.

 

    -17-

     

    

 

Section
6.2 Diligence. Each Party shall use Commercially Reasonable Efforts to carry out its obligations under each Work Plan.
Following [*] Amgen shall (directly and/or through one or more Affiliates and/or Sublicensees) use Commercially Reasonable Efforts
to develop and commercialize the applicable Product under such Collaboration Program in the Territory.

 

Section
6.3 Reports. For each Product, during the period from the end of the applicable Preclinical R&D Term until the
First Commercial Sale of such Product, Amgen shall provide EnteraBio with reports [*] per Calendar Year of the status of Amgen’s
and its Affiliates’ and Sublicensees’ activities related to the Exploitation of such Product during the preceding
[*] period. In addition, the Parties shall conduct [*] teleconference meetings to discuss the progress of each Collaboration Program.
All reports and other Information provided by Amgen under this Section 6.3 will be Amgen’s Confidential Information subject
to the terms of Article 12.

 

Article
7. FEES, ROYALTIES, & PAYMENTS

 

Section
7.1 Technology Access Payment; Upfront Payment and R&D Funding.

 

7.1.1       
Technology Access Payment; Upfront Payment.  For the Initial Program, Amgen shall pay to EnteraBio a non-refundable,
non-creditable payment equal to Seven Hundred and Twenty Five Thousand Dollars ($725,000) within thirty (30) days after the Effective
Date (the “Technology Access Payment”). For each Post Effective-Date Program, Amgen shall pay to EnteraBio
a non-refundable, non-creditable payment equal to [*] within thirty (30) days of the parties entering into the applicable Work
Plan (the “Upfront Payment”).

 

7.1.2       
R&D Costs.

 

(a)              
Amgen shall pay to EnteraBio for the performance of EnteraBio’s activities under the Work Plan of each Post Effective-Date
Program during the one (1) year period following the date in which the Parties agree in writing on the initiation of the applicable
Post Effective-Date Program (the “First Year”), an aggregate amount of Two Hundred and Twenty-Five Thousand
Dollars ($225,000) (such payment amount contemplated in this Section 7.1.2(a), the “First Year R&D Payment”).

 

(b)              
Amgen shall pay to EnteraBio for the performance of EnteraBio’s activities under the Work Plan of each Collaboration
Program, during the one (1) year period following the one (1) year anniversary of the date in which the Parties agreed in writing
on the initiation of the applicable Collaboration Program, which for the Initial Program shall mean the Effective Date (the “Second
Year”), an aggregate amount of Four Hundred and Fifty Thousand Dollars ($450,000) (such payment amount contemplated
in this Section 7.1.2(b), the “Second Year R&D Payment”). 

 

(c)              
Within thirty (30) days after the initiation of the applicable Post Effective-Date Program, Amgen shall pay to EnteraBio
an amount equal to Two Hundred Twenty-Five Thousand Dollars ($225,000) as a prepayment for the First Year R&D Payment. 

 

    -18-

     

    

 

(d)              
Within thirty (30) days after the one (1) year anniversary of the Effective Date, or the initiation of the applicable Collaboration
Program, as applicable, Amgen shall pay to EnteraBio an amount equal to Two Hundred Twenty-Five Thousand Dollars ($225,000) as
a prepayment for the Second Year R&D Payment.

 

(e)              
Within thirty (30) days after the two (2) year anniversary of the Effective Date, or the initiation of the applicable Collaboration
Program, as applicable, Amgen shall pay to EnteraBio an amount equal to Two Hundred Twenty-Five Thousand Dollars ($225,000) for
the remaining balance of the Second Year R&D Payment.

 

(f)               
The Parties shall discuss in good faith additional Amgen payments to EnteraBio for R&D activities performed by EnteraBio
under the Work Plan of any Collaboration Program following the Second Year. 

 

Section
7.2 Milestone Payments.

 

7.2.1       
Amgen shall pay to EnteraBio one-time milestone payments (“Milestone Payments”) following the first
occurrence of the corresponding milestone events (“Milestone Events”) as set forth in the following tables:

 

(i)
Milestone Payments for the Initial Program, subject to Section 3.8:

 

(a) GLP
Toxicology Study Milestone Events for the Initial Program 

 

	Milestone
    Event	Milestone
    Payment
	Initiation
    of first GLP Toxicology Study of a Product under the Initial Program	[*]

 

(b) Other
Development Milestone Events for the Initial Program

 

	Milestone Event	Milestone
    Payment
	Initiation
    of first Phase 1 Clinical Trial of a Product under the Initial Program	[*]
	Initiation
    of first Phase 2 Clinical Trial of a Product under the Initial Program	[*]
	Initiation
    of first Phase 3 Clinical Trial of a Product under the Initial Program	[*]

 

    -19-

     

    

 

(c) Commercial
Milestone Events for the Initial Program

 

	Milestone Event	Milestone
        Payment

         

	First
    Commercial Sale of a Product under the Initial Program	[*]
	Worldwide
    Net Sales of Products under the Initial Program exceed [*] in a calendar year	[*]
	Worldwide
    Net Sales of Products under the Initial Program exceed [*] in a calendar year	[*]
	Worldwide
    Net Sales of Products under the Initial Program exceed [*] in a calendar year	[*]

 

(ii)
Milestone Payments for each of the Second and Third Collaboration Program:

 

(a) Development
Milestone Events for each of the Second and Third Collaboration Program 

 

	Milestone Event	Milestone
        Payment

         

	Initiation
    of first GLP Toxicology Study of a Product under the applicable Post-Effective Date Program	[*]

 

(b) Development
Milestone Events for each of the Second and Third Collaboration Program

 

	Milestone Event	Milestone
        Payment

         

	Initiation
    of first Phase 1 Clinical Trial of a Product under the applicable Post-Effective Date Program	[*]

 

    -20-

     

    

 

	Milestone Event	Milestone
    Payment
	Initiation
    of first Phase 2 Clinical Trial of a Product under the applicable Post-Effective Date Program	[*]
	Initiation
    of first Phase 3 Clinical Trial of a Product under the applicable Post-Effective Date Program	[*]

 

(c) Commercial
Milestone Events for each of the Second and Third Collaboration Program

 

	Milestone Event	Milestone
    Payment
	First
    Commercial Sale of a Product under the applicable Post-Effective Date Program	[*]
	Worldwide
    Net Sales of Products under the applicable Post-Effective Date Program exceed [*] in a calendar year	[*]
	Worldwide
    Net Sales of Products under the applicable Post-Effective Date Program exceed [*] in a calendar year	[*]
	Worldwide
    Net Sales of Products under the applicable Post-Effective Date Program exceed [*] in a calendar year	[*]

 

7.2.2       
The Parties agree that Amgen shall pay to EnteraBio the applicable Milestone Payment in the manner described below
after the first occurrence of the applicable Milestone Event with respect to the first Product under a given Collaboration Program.
For clarity, each Milestone Payment payable pursuant to Section 7.2.1(i) and (ii), as applicable, is payable only once per Collaboration
Program and the maximum Milestone Payment amount payable for Products with respect to the Initial Program under Section 7.2.1(i)
and [*]. The maximum Milestone Payment amount payable for Products with respect to each Post-Effective Date Program is [*]. No
Milestone Payment shall be payable for subsequent or repeated achievements of such Milestone Event with one or more of the same
or different Products under a Collaboration Program. Each of the Milestone Payments shall be non-refundable and non-creditable.
Amgen shall report to EnteraBio its achievement of each Milestone Event for which payment to EnteraBio is due promptly after Amgen
determines such achievement has occurred, and EnteraBio shall invoice Amgen for the applicable Milestone Payment. Amgen will pay
each such invoice within forty-five (45) days of its receipt thereof.

 

    -21-

     

    

 

Section
7.3 Royalties.

 

7.3.1       
Royalties. Subject to the provisions of this Section 7.3 and Section 3.8, Amgen shall pay to EnteraBio, with
respect to Products, on a Product-by-Product and country-by-country basis, royalties on annual Net Sales of Products during the
applicable Royalty Term, calculated as set forth in Section 7.3.3. Royalties will be payable on a calendar quarterly basis and
any such payments shall be made within [*] after the end of the calendar quarter during which the applicable Net Sales of Products
occurred.

 

7.3.2       
Royalty Term. Amgen’s obligation to pay royalties with respect to a Product in a particular country shall
commence upon the First Commercial Sale of such Product in such country and shall expire on a country-by-country and Product-by-Product
basis on the later of (a) the date on which the sale of the Product is no longer Covered by a Valid Claim of an EnteraBio Patent
or Collaboration Patent, and (b) the tenth (10th) anniversary of the First Commercial Sale of such Product in such country (the
“Royalty Term”).

 

7.3.3       
Royalty Rates. The royalty rates payable under Section 7.3.1 shall be calculated as follows:

 

	Aggregate Annual Net Sales of Products under a
    Collaboration Program	Royalty Rate
	(a) With respect to the Initial Program: commencing
    on the first year in which aggregate annual Net Sales of Products under the Initial Program is greater than or equal to [*],
    for aggregate annual Net Sales of Products less than [*]; and (b) With respect to each Post-Effective Date Program: for aggregate
    annual Net Sales of Products less than [*].  	[*]
	If aggregate annual Net Sales of Products
    under a Collaboration Program is greater than or equal to [*] and less than [*] 	[*]

 

    -22-

     

    

 

	If aggregate annual Net Sales
    of Products under a Collaboration Program greater than or equal to [*]	[*]

 

For
the avoidance of doubt, if the sale of a Product is Covered by more than one Valid Claim, the above royalty shall be paid only
once.

 

7.3.4       
Royalty Reduction.

 

(a)              
On a country-by-country and Product-by-Product basis, in the event that (i) the Exploitation of a Product is not Covered
by a Valid Claim of an EnteraBio Patent or Collaboration Patent in such country and the Royalty Term for such Product in such
country has not expired, and (ii) a Third Party commences commercial sale of a Generic Version of a Product in a country, then
the royalty rates set forth in Section 7.3.3 with respect to Net Sales for such Product in such country shall be reduced by [*],
effective as of the later of: (x) the date such Product is no longer Covered by a Valid Claim of an EnteraBio Patent or Collaboration
Patent in such country; and (y) the first day of the first calendar quarter following the calendar quarter in which Net Sales
of such Product in the applicable country decrease by more than[*] from the Net Sales of such Product in such country in the calendar
quarter immediately preceding the first commercial sale of such Generic Version. 

 

7.3.5       
Mutual Convenience of the Parties. The royalty and other payment obligations set forth hereunder have been agreed
to by the Parties for the purpose of reflecting and advancing their mutual convenience, including the ease of calculating and
paying royalties and other amounts required hereunder.

 

Section
7.4 Invoicing. To the extent an invoice is required to be submitted to Amgen hereunder, such invoice shall be addressed
to:

 

Amgen
Inc.

Accounts
Payable

PO
Box 667

Newbury
Park, CA 91319-0667

Attention:
[*]

 

Section
7.5 Method of Payment. Unless otherwise agreed by the Parties, all payments due from Amgen under this Agreement shall
be paid by wire transfer or electronic funds transfer of immediately available funds to an account designated in writing by EnteraBio.
After the First Commercial Sale of the first Product and until expiration of the last Royalty Term for a Product, Amgen shall
prepare and deliver to EnteraBio reports of the sale of Products by the Selling Parties for each calendar quarter together with
the corresponding royalty payment or other consideration to be paid to EnteraBio in accordance with Section 7.3.1, specifying
on a Product-by-Product and country-by-country basis, a detailed and itemized calculation of Net Sales in a manner that is consistent
with the method generally used by the Amgen Finance Department to track such information for Amgen’s other commercialized
products in the Territory.

 

    -23-

     

    

 

Section
7.6 Currency Conversion. All royalties shall be payable in full in U.S. Dollars. Any sales of Products incurred in
a currency other than U.S. Dollars shall be converted to the U.S. Dollar equivalent using Amgen’s then-current standard
exchange rate methodology as applied to its external reporting for the conversion of foreign currency sales into U.S. Dollars.

 

Section
7.7 Records and Audits. The Parties shall keep complete and accurate records of payments required under this Agreement
for a period of [*] after the end of the calendar year in which any such payment was due. Each Party will have the right, [*]
annually at its own expense, to have a nationally recognized, independent, certified public accounting firm, selected by it and
subject to the other Party’s prior written consent (which shall not be unreasonably withheld, conditioned or delayed), review
any such records of such other Party and its Affiliates and their Sublicensees upon reasonable written notice (which shall be
no less than thirty (30) days’ prior written notice) and during regular business hours and under obligations of strict confidence,
for the sole purpose of verifying the basis and accuracy of payments made under this Agreement for the period under audit. No
calendar year will be subject to audit under this Section 7.7 more than once. The audited Party will receive a copy of each such
report concurrently with receipt by the auditing Party, and such accounting firm shall report to the Parties whether or not such
calculations are correct and the amount of any discrepancy. Each Party agrees to treat the results of any such review of the audited
Party’s and its Affiliates’ records under this Section 7.7 as Confidential Information of the audited Party and subject
to the terms of Article 12. Should such inspection lead to the discovery of a discrepancy to either EnteraBio’s or Amgen’s
detriment, the other Party will promptly pay EnteraBio or Amgen, as applicable, any undisputed amount of the discrepancy together
with interest at the rate set forth in Section 7.8. If an audit reveals an underpayment of more than the greater of [*] of the
amount that should have been paid to EnteraBio during the audited period, Amgen shall bear the full expenses of the audit.

 

Section
7.8 Late Payments. In the event that any payment due hereunder is not made when due, the payment shall accrue interest
beginning on the day following the due date thereof, calculated at the annual rate of [*] the prime interest rate quoted by The
Wall Street Journal, Internet U.S. Edition at www.wsj.com on the date said payment is due, the interest being compounded on
the last day of each calendar quarter; provided, however, that in no event shall said annual interest rate exceed the maximum
rate permitted by Law. Each such payment when made shall be accompanied by all interest so accrued. With respect to any disputed
payments, no interest payment shall be due until such dispute is resolved and the interest which shall be payable thereon shall
be based on the finally-resolved amount of such payment, calculated from the original date on which the disputed payment was due
through the date on which payment is actually made.

 

Section
7.9 Taxes.

 

7.9.1       
Withholding. In the event that any Law requires Amgen to withhold taxes with respect to any payment to be made
by Amgen pursuant to this Agreement, Amgen will notify EnteraBio of such withholding requirement prior to making the payment to
EnteraBio and provide such assistance to EnteraBio, including the provision of such standard documentation as may be required
by a tax authority, as may be reasonably necessary in EnteraBio’s efforts to claim an exemption from or reduction of such

 

    -24-

     

    

 

taxes.
Amgen will, in accordance with such Law, withhold taxes from the amount due, remit such taxes to the appropriate tax authority,
and furnish EnteraBio with proof of payment of such taxes within thirty (30) days following the payment. If taxes are paid to
a tax authority, Amgen shall provide reasonable assistance to EnteraBio to obtain a refund of taxes withheld, or obtain a credit
with respect to taxes paid. If any taxes are so withheld, such withheld amounts shall be treated for all purposes of this Agreement
as having been paid to EnteraBio. EnteraBio shall provide Amgen any tax forms (including Internal Revenue Service Form W-8BEN
or W-8ECI or other applicable Internal Revenue Service Form) that may be reasonably necessary in order for Amgen to determine
whether to withhold tax on any such payments or to withhold tax on such payments at a reduced rate under applicable tax Law, including
any applicable bilateral income tax treaty.

 

7.9.2       
VAT. All payments due to EnteraBio from Amgen pursuant to this Agreement shall be paid exclusive of any value-added
tax (“VAT”) (which, if applicable, shall be payable by Amgen upon receipt of a valid VAT invoice). If EnteraBio
determines that it is required to report any such tax, Amgen shall promptly provide EnteraBio with applicable receipts and other
documentation necessary or appropriate for such report. For clarity, this Section 7.9.2 is not intended to limit Amgen’s
right to deduct value-added taxes in determining Net Sales.

 

Article
8. Intellectual property

 

Section
8.1 Intellectual Property Ownership.

 

8.1.1       
Background IP. Each Party will own all right, title and interest in its Background IP.

 

8.1.2       
Collaboration IP. Ownership of Collaboration IP shall follow inventorship. Inventorship will be determined according
to U.S. Patent Law (without reference to any conflict of law principles). Amgen, on behalf of itself and its Affiliates and Sublicensees,
hereby grants and agrees to grant to EnteraBio a fully paid up, perpetual, worldwide, non-exclusive license, with a right to grant
sublicenses, under Collaboration IP solely owned by Amgen, its Affiliates and Sublicenses, solely to the extent such Collaboration
IP claims an Improvement to the EnteraBio Platform, to Exploit such Improvement to the EnteraBio Platform for all purposes, subject
to the exclusivity granted to Amgen under this Agreement.

 

8.1.3       
Joint IP. Except as expressly provided in this Agreement, it is understood that neither Party will have any
obligation to obtain any approval or consent of, nor pay a share of the proceeds to or account to, the other Party to practice,
enforce, license, assign or otherwise exploit inventions or intellectual property owned jointly by the Parties hereunder, and
each Party hereby waives any right it may have under the laws of any jurisdiction to require such approval, consent or accounting.
Each Party agrees to cooperate with the other Party, as reasonably requested, and to take such actions as may be required to give
effect to this Section 8.1.3 in a particular country within the Territory. Notwithstanding the foregoing, Amgen shall retain all
rights to the antibody nucleic acid sequences provided to EnteraBio under this Agreement, along with the polypeptide sequences,
and nucleic acids encoded by such said nucleic acid sequences, Derivatives of said polypeptide sequences and nucleic acids encoding
said Derivatives. “Derivatives” shall include [*].

 

    -25-

     

    

 

Section
8.2 Patent Prosecution and Maintenance.

 

8.2.1       
EnteraBio Patent(s). Other than with respect to any Collaboration Patents, EnteraBio will be solely responsible,
at its own cost, for preparing, filing, prosecuting (including, but not limited to provisional, reissue, continuing, continuation-in-part,
and substitute applications and any foreign counterparts thereof), and maintaining all EnteraBio Patents and conducting any interferences
and oppositions or similar proceedings relating to EnteraBio Patents. Amgen acknowledges and agrees that (a) neither EnteraBio
nor any of its Affiliates will have any liability of any kind relating to the preparation, filing, prosecution and maintenance
of Patent Rights as provided in this Section 8.2.1; and (b) EnteraBio and its Affiliates have the right to cease all activities
relating to the preparation, filing, prosecution or maintenance of any Patent Rights as provided in this Section 8.2.1 for any
reason, in which case EnteraBio will promptly inform Amgen of such planned cessation.

 

8.2.2       
Amgen Patent(s). Other than with respect to any Collaboration Patents, Amgen will be solely responsible, at
its own cost, for preparing, filing, prosecuting (including, but not limited to provisional, reissue, continuing, continuation-in-part,
and substitute applications and any foreign counterparts thereof), and maintaining all Amgen Patents and conducting any interferences
and oppositions or similar proceedings relating to Amgen Patents. EnteraBio acknowledges and agrees that (a) neither Amgen nor
any of its Affiliates will have any liability of any kind relating to the preparation, filing, prosecution and maintenance of
Patent Rights as provided in this Section 8.2.2; and (b) Amgen and its Affiliates have the right to cease all activities relating
to the preparation, filing, prosecution or maintenance of any Patent Rights as provided in this Section 8.2.2 for any reason,
in which case Amgen will promptly inform EnteraBio of such planned cessation.

 

8.2.3       
Collaboration Patents. EnteraBio will be primarily responsible, at its own cost, for preparing, filing, prosecuting
(including, but not limited to provisional, reissue, continuing, continuation-in-part, and substitute applications and any foreign
counterparts thereof), and maintaining all Patent Rights constituting Collaboration Patents that: (i) solely claim Improvements
to the EnteraBio Platform; or (ii) solely claim Collaboration Know-How generated solely by EnteraBio after the applicable Preclinical
R&D Term or (iii) pursuant to Section 8.1.2 are owned solely by EnteraBio (the “EnteraBio Prosecuted Collaboration
Patents”), and conducting any interferences and oppositions or similar proceedings relating to such Patent Rights. Other
than the EnteraBio Prosecuted Collaboration Patents, Amgen will be primarily responsible, at its own cost, for preparing, filing,
prosecuting (including, but not limited to provisional, reissue, continuing, continuation-in-part, and substitute applications
and any foreign counterparts thereof), and maintaining all other Patent Rights constituting Collaboration Patents and conducting
any interferences and oppositions or similar proceedings relating to such Patent Rights. The filing Party will provide the non-filing
Party with copies of and an opportunity to review and comment upon the text of the applications relating to the applicable Collaboration
Patents at least thirty (30) days before filing; provided, however, that if it is not reasonably practicable to provide
such application in such thirty (30) day period, then the filing Party will provide either a draft copy of such application or
a statement of intent to file such application in such thirty (30) day period. The filing Party will provide the non-filing Party
with a copy of each submission made to and document received from a patent authority, court or other tribunal regarding any Collaboration
Patent reasonably promptly after making such filing or receiving such document, including a copy of each application for each
Collaboration Patent as filed together with notice of its filing date and application number. The filing Party will keep the non-filing
Party advised of the status of all material communications, and actual and prospective filings or

 

    -26-

     

    

 

submissions
regarding the Collaboration Patents, and will give the non-filing Party copies of and an opportunity to review and comment on
any such material communications, filings and submissions proposed to be sent to any patent authority or judicial body. The filing
Party will consider in good faith the non-filing Party’s comments on such communications, filings and submissions for the
Collaboration Patents. With respect to any filings or other materials provided to the non-filing Party under this Section 8.2.3,
the filing Party will have the right to redact information relating to manufacturing, CMC or devices, any product other than Products
or any Know-How other than Collaboration Know-How from any such filings and materials. In the event either Party declines to file,
prosecute or maintain any of the foregoing Patent Rights, elects to allow any Patent Rights to lapse in any country, or elects
to abandon any Patent Rights (in each case to the extent contained in the Collaboration Patents) before all appeals within the
respective patent office have been exhausted (each, an “Abandoned Patent Right”), then: (1) such Party
shall provide the other Party with reasonable notice of such decision so as to permit the non-abandoning Party to decide whether
to file, prosecute or maintain such Abandoned Patent Rights and to take any necessary action (which notice shall, in any event,
be given no later than sixty (60) days prior to the next deadline for any action that may be taken with respect to such Abandoned
Patent Right with the U.S. Patent & Trademark Office or any foreign patent office); (2) the non-abandoning Party, at
the non-abandoning Party’s expense, may assume control of the filing, prosecution or maintenance of such Abandoned Patent
Rights; (3) the non-abandoning Party shall have the right, at its expense, to transfer the responsibility for such filing,
prosecution and maintenance of such Abandoned Patent Rights to patent counsel (outside or internal) selected by the non-abandoning
Party; and (4) the abandoning Party shall, at the non-abandoning Party’s reasonable request and at the non-abandoning
Party’s expense, assist and cooperate in the filing, prosecution and maintenance of such Abandoned Patent Rights.

 

Section
8.3 Patent Term Extensions. The Parties will cooperate with each other in gaining Patent Right term extension where
applicable to Products, and in the case of any disagreement, Amgen shall have the final say as to term extension for any Patent
Right claiming the composition of matter or method of use of a Product.

 

Section
8.4 Defense and Settlement of Third Party Claims. If either (a) any Product Exploited by or under authority of either
Party becomes the subject of a Third Party’s claim or assertion of infringement of a patent, or (b) a declaratory judgment
action is brought naming either Party as a defendant and alleging invalidity of any of the Patent Rights contained in Collaboration
Patents, EnteraBio Patents or Amgen Patents, the Party first having notice of the claim or assertion shall promptly notify the
other Party, and the Parties shall promptly confer to consider the claim or assertion and the appropriate course of action. Unless
the Parties otherwise agree in writing, each Party shall have the right to defend itself against a suit that names it as a defendant
(the “Defending Party”). Neither Party shall enter into any settlement of any claim described in this Section
8.4 that admits to the invalidity or unenforceability of any Patent Right Controlled by the other Party or jointly by the Parties
(or otherwise affects the scope, validity or enforceability of such Patent Right), incurs any financial liability on the part
of any other Party or requires an admission of liability, wrongdoing or fault on the part of the other Party without such other
Party’s written consent. In any event, the other Party shall reasonably assist the Defending Party and cooperate in any
such litigation at the Defending Party’s request and expense. Additionally, if the Defending Party is not the Party that
Controls the Patent Right in question, then the other Party has the right to join any such action.

 

Section
8.5 Enforcement.

 

    -27-

     

    

 

8.5.1       
Notice of Infringement. The Parties shall inform each other promptly of any infringement or colorable cause
of action for infringement of any Patent Right within the Collaboration Patents, EnteraBio Patents or Amgen Patents, and the Parties
shall promptly confer to consider the best appropriate course of action.

 

8.5.2       
Enforcement. In the event that such infringement or alleged infringement is with respect to a product that has
the same primary mechanism of action as a Product, then Amgen shall have the right to enforce the following Patent Rights against
any such infringement or alleged infringement thereof: with respect to (a) an Amgen Patent, such right shall be a sole right and
shall not require the prior written consent of EnteraBio, (b) EnteraBio Patents or Collaboration Patents which constitute an Improvement
of the EnteraBio Platform, such right shall require the prior written consent of EnteraBio, and (c) any Patent Right within the
Collaboration Patents, other than the aforementioned, such right shall be a sole right and shall not require the prior written
consent of EnteraBio. Amgen shall at all times keep EnteraBio informed as to the status thereof. In such case, Amgen may, at its
own expense, institute suit against any infringer or alleged infringer and control and defend such suit in a manner consistent
with the terms and provisions hereof and recover any damages, awards or settlements resulting therefrom, subject to Section 8.5.5.
EnteraBio shall reasonably cooperate in any such litigation at Amgen’s expense. [*]. In the event that Amgen does not elect
to enforce any Patent Right within the EnteraBio Patents or Collaboration Patents, then EnteraBio shall be entitled to do so,
[*].

 

8.5.3       
Progress Reporting. The Party initiating or defending any such enforcement action (the “Enforcing Party”)
shall keep the other Party reasonably informed of the progress of any such enforcement action, and such other Party shall have
the individual right to participate with counsel of its own choice at its own expense.

 

8.5.4       
Allocation of Recoveries. [*]

 

[*]

 

[*]

 

Section
8.6 Trademarks. As between the Parties, Amgen shall own all right, title and interest in and to any trademarks adopted
by Amgen for use with a Product, and shall be responsible for the registration, filing, maintenance and enforcement thereof.

 

    -28-

     

    

 

Article
9. REPRESENTATIONS, WARRANTIES AND COVENANTS

 

Section
9.1 Mutual Representations and Warranties. Each of Amgen and EnteraBio represents and warrants to the other Party,
as of the Effective Date, that:

 

(a)                    
it is duly incorporated and validly existing under, with respect to Amgen, the Law of Delaware, and with respect to EnteraBio,
the Law of the State of Israel, and has full corporate power and authority to enter into this Agreement and to carry out the provisions
hereof;

 

(b)                    
it is duly authorized to execute and deliver this Agreement and to perform its obligations hereunder, and the individual
executing this Agreement on its behalf has been duly authorized to do so by all requisite corporate action; and

 

(c)                    
this Agreement is legally binding upon it and enforceable in accordance with its terms and the execution, delivery and
performance of this Agreement by it have been duly authorized by all necessary corporate action and do not and will not: (x) conflict
with, or constitute a default under, any agreement, instrument or understanding, oral or written, to which it is a party or by
which it may be bound, or violate any material applicable Law or (y) require any consent or approval of its stockholders or similar
action.

 

Section
9.2 Additional EnteraBio Representations, Warranties and Covenants. EnteraBio represents and warrants to Amgen that,
as of the Effective Date (except as specifically stated otherwise):

 

(a)                    
EnteraBio has full legal or beneficial title and ownership of, or an exclusive license to, the EnteraBio Patents as is
necessary to grant the licenses (or sublicenses) to Amgen to such EnteraBio Patents that EnteraBio purports to grant pursuant
to this Agreement;

 

(b)                    
EnteraBio has the rights necessary to grant the licenses to Amgen under EnteraBio Licensed Know-How that EnteraBio purports
to grant pursuant to this Agreement;   

 

(c)                    
To EnteraBio’s knowledge, the EnteraBio Patents licensed to EnteraBio and its Affiliates are not subject to, any
liens or encumbrances, and EnteraBio has not, and will not during the Term, grant any right to any Third Party under or with respect
to the EnteraBio IP that would conflict with the rights granted to Amgen hereunder or terminate any rights granted by a Third
Party to EnteraBio or its Affiliates that are further granted to Amgen hereunder; 

 

(d)              
Except as disclosed in EnteraBio’s SEC filings, no claim or action has been brought or, to EnteraBio’s knowledge,
threatened by any Third Party alleging that (i) the EnteraBio Patents are invalid or unenforceable or (ii) use of the EnteraBio
IP infringes or misappropriates or would infringe or misappropriate any right of any Third Party, and no EnteraBio Patent is the
subject of any interference, opposition, cancellation or other protest proceeding. EnteraBio has not received any written notice
from any Third Party asserting or alleging that the development, manufacture, use or sale of any Product infringes the rights
of such Third Party in the Territory;

 

(e)              
There are no pending actions, claims, investigations, suits or proceedings against EnteraBio or its Affiliates, at law
or in equity, or before or by any Regulatory Authority, and neither EnteraBio nor any of its Affiliates has received any written
notice regarding any pending or threatened

 

    -29-

     

    

 

actions,
claims, investigations, suits or proceedings against EnteraBio or such Affiliate, at law or in equity, or before or by any Regulatory
Authority, in either case with respect to the EnteraBio IP; and

 

(f)               
To EnteraBio’s knowledge, no Third Party, including any current or former employee or consultant of EnteraBio, is
infringing or misappropriating or has infringed or misappropriated the EnteraBio IP.

 

Section
9.3 Additional Amgen Representations, Warranties and Covenants. Amgen represents and warrants to EnteraBio that, as
of the Effective Date (except as specifically stated otherwise):

 

(a)                    
Amgen has full legal or beneficial title and ownership of, or an exclusive license to, the Amgen Patents as is necessary
to grant the licenses (or sublicenses) to EnteraBio to such Amgen Patents that Amgen purports to grant pursuant to this Agreement;

 

(b)                    
The Amgen Patents owned by Amgen and its Affiliates are not subject to, and to Amgen’s knowledge the Amgen Patents
licensed to Amgen and its Affiliates are not subject to, any liens or encumbrances and Amgen has not granted to any Third Party
any rights or licenses under such Patent Rights that would conflict with the licenses granted to EnteraBio hereunder;

 

(c)                    
Amgen has no knowledge of any claim or litigation that has been brought or threatened in writing by any Third Party alleging
that (i) the Amgen Patents are invalid or unenforceable or (ii) the use of the Amgen IP infringes or misappropriates or would
infringe or misappropriate any right of any Third Party, and no Amgen Patent is the subject of any interference, opposition, cancellation
or other protest proceeding.

 

Section
9.4 Mutual Covenants.

 

(a)              
Employees, Consultants and Contractors. Each Party covenants that it has obtained or will obtain written agreements
from each of its employees, consultants and contractors who perform research or development activities pursuant to this Agreement,
which agreements will obligate such persons to obligations of confidentiality and non-use and to assign inventions in a manner
consistent with the provisions of this Agreement.

 

(b)              
Debarment. Each Party represents, warrants and covenants to the other Party that it is not debarred, excluded, disqualified,
or the subject of disbarment, exclusion or disqualification proceedings under the U.S. Food, Drug and Cosmetic Act or comparable
Laws in any country or jurisdiction other than the U.S. and, to its knowledge, does not, and will not during the Term knowingly,
employ or use, directly or indirectly, including through Affiliates or Sublicensees, the services of any person who is debarred,
excluded, disqualified, or the subject of disbarment, exclusion or disqualification proceedings in connection with activities
relating to any Product. In the event that either Party becomes aware of the debarment, exclusion or disqualification or threatened
debarment, exclusion or disqualification of any person providing services to such Party, directly or indirectly, including through
Affiliates or Sublicensees, which directly or indirectly relate to activities contemplated by this Agreement, such Party shall
promptly notify the other Party in writing and such Party shall cease employing, contracting with, or retaining any such person
to perform any such services.

 

    -30-

     

    

 

(c)              
Compliance.

 

(i)                
Each Party agrees, on behalf of itself and its officers, directors, employees, Affiliates and agents, that, in connection
with the matters that are the subject of this Agreement, and the performance of its obligations hereunder:

 

		(a)	It
                                         shall use its commercially reasonable efforts to comply with all applicable (i) U.S.
                                         Laws prohibiting the re-export, directly or indirectly, of certain controlled U.S.-origin
                                         items without a license to parties located in certain countries or appearing on certain
                                         U.S. Government lists of restricted parties; (ii) U.S. Laws prohibiting participation
                                         in non-U.S. boycotts that the United States does not support; (iii) U.S. Laws prohibiting
                                         the sale of products to parties from any country subject to U.S. economic sanctions or
                                         who are identified on related U.S. Government lists of restricted parties; and (iv) data
                                         privacy laws of the applicable jurisdiction, including the national and sub-national
                                         laws based on the European Union Data Protection Directive 95/46/EC, and all data breach
                                         notification and information securities laws and regulations specific thereto.

 

		(b)	It
                                         will comply with the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act
                                         2010, as amended, and any other applicable Law relating to or concerning public or commercial
                                         bribery or corruption (collectively, “Anti-Bribery and Anti-Corruption Laws”)
                                         and its applicable anti-corruption policies (“Anti-Corruption Policies”),
                                         and will not take any action that will cause the other Party or its Affiliates to be
                                         in violation of any such laws or policies.

 

		(c)	It
                                         will not, directly or indirectly, pay, offer or promise to pay, or authorize the payment
                                         of any money, or give, offer or promise to give or authorize the giving of anything of
                                         value to any Public Official or Entity for the purpose of influencing the acts of such
                                         Public Official or Entity to induce them to use their influence with any Governmental
                                         Authority, or obtaining or retaining business or any improper advantage in connection
                                         with this Agreement, or that would otherwise violate any Anti-Bribery and Anti-Corruption
                                         Laws or Anti-Corruption Policies.

 

		(d)	It
                                         will not directly or indirectly solicit, receive or agree to accept any payment of money
                                         or anything else of value in violation of the Anti-Bribery and Anti-Corruption Laws or
                                         the Anti-Corruption Policies.

 

(ii)             
Each Party, on behalf of itself and its officers, directors, employees, Affiliates, agents and Representatives, represents
and warrants to the other Party that, in connection with the matters that are the subject of this Agreement, and the performance
by each Party of its obligations hereunder:

 

		(a)	To
                                         its knowledge, as of the Effective Date, it and its Affiliates have not committed any
                                         Material Anti-Corruption Law Violation, other than, in the case of Amgen, the mis-promotion
                                         activities preceding the Corporate Integrity Agreement, entered into between Amgen and
                                         the Office of the Inspector General of the Department of Health and Human Services in
                                         December 2012.

 

    -31-

     

    

 

		(b)	To
                                         its knowledge, none of its contracts, licenses or other assets that are the subject of
                                         this Agreement were procured in violation of the Anti-Bribery and Anti-Corruption Laws.

 

(iii)           
Each Party will keep and maintain accurate books, accounts, invoices and reasonably detailed records in connection with
the performance of its obligations under, and payments made in connection with, this Agreement, including all records required
to establish compliance with the provisions of this Section 9.4(c), until the later of (a) [*] after the end of the period to
which such books and records pertain or (b) the expiration of the applicable statute of limitations (or any extension thereof).

 

(iv)            
If a Party becomes aware that any of its officers, directors or employees becomes during the Term a Public Official or
Entity in a position to take or influence official action for or against a Party in connection with the performance of its obligations
under this Agreement, that Party will promptly notify the other Party. A Party shall notify the other Party upon receiving a formal
notification that it is the target of a formal investigation by a Governmental Authority for a Material Anti-Corruption Law Violation
or upon receipt of information from any of its representatives that any of them is the target of a formal investigation by a Governmental
Authority for a Material Anti-Corruption Law Violation in connection, in either case in connection with this Agreement.

 

(v)              
If either Party requests that any other Party complete a compliance certification certifying compliance with this Section
9.4(c), which request shall occur no more than [*] per calendar year, such other Party shall promptly complete and deliver such
compliance certification truthfully and accurately. If either Party requests, in connection with a Corporate Integrity Agreement
or similar arrangement with a Governmental Authority, that any other Party complete a compliance certification certifying adherence
to and compliance with such other Party’s code of conduct and compliance program with respect to such other Party’s
activities under this Agreement, which request shall occur no more than [*] per calendar year, such other Party shall cooperate
with the first Party to promptly complete and deliver such compliance certification truthfully and accurately, and should there
be reasonable additional requests of such other Party as a result of a Corporate Integrity Agreement or similar arrangement with
a Governmental Authority of the requesting Party, such other Party shall comply with such requests at the requesting Party’s
cost and expense.

 

(vi)            
In the event that a Party has a good faith reason to believe that the other Party may be in breach or violation of any
representation, warranty or undertaking in this Section 9.4(c), such Party shall have the right to conduct an examination and
audit of relevant books and records of the other Party and, during the pendency of such examination, to suspend any obligations
on the part of such Party to the other Party. In the event that a Party becomes aware, whether or not through audit, that the
other Party is in breach of or in violation of any representation, warranty or undertaking in this Section 9.4(c), then that Party
shall have the right to take such steps as are reasonably necessary in order to avoid a violation or continuing violation of the
Anti-Bribery and Anti-Corruption Laws, including by requesting such additional representations, warranties, undertakings and other
provisions including a further audit as it believes in good faith are reasonably necessary.

 

    -32-

     

    

 

Section
9.5 Disclaimer. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS ARTICLE 9, NEITHER PARTY MAKES ANY REPRESENTATIONS
OR EXTENDS ANY WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY, QUALITY, FITNESS FOR
A PARTICULAR PURPOSE, NONINFRINGEMENT, OR VALIDITY OF PATENT CLAIMS. NOTHING IN THIS AGREEMENT SHALL BE CONSTRUED AS A REPRESENTATION
MADE OR WARRANTY GIVEN BY EITHER PARTY THAT EITHER PARTY WILL BE SUCCESSFUL IN OBTAINING ANY PATENT RIGHTS, OR THAT ANY PATENT
RIGHTS WILL ISSUE BASED ON A PENDING APPLICATION. WITHOUT LIMITING THE RESPECTIVE RIGHTS AND OBLIGATIONS OF THE PARTIES EXPRESSLY
SET FORTH HEREIN, EACH PARTY SPECIFICALLY DISCLAIMS ANY GUARANTEE THAT THE PRODUCTS WILL BE SUCCESSFUL, IN WHOLE OR IN PART.

 

Article
10. INDEMNIFICATION

 

Section
10.1 Indemnity.

 

10.1.1   
By EnteraBio. EnteraBio agrees to defend Amgen, its Affiliates, and each of their respective directors, officers,
employees and agents (the “Amgen Indemnified Parties”), at EnteraBio’s cost and expense, and will indemnify
and hold Amgen and the other Amgen Indemnified Parties harmless from and against any claims, losses, costs, damages, fees or expenses
(including reasonable legal fees and expenses) (collectively, “Losses”) to the extent resulting from any claims,
actions, suits or proceedings brought by a Third Party (including product liability claims) (a “Third Party Claim”)
arising out of (a) the gross negligence or willful misconduct of EnteraBio, its Affiliates or their respective Sublicensees
in connection with its activities under this Agreement; (b) the material breach of this Agreement or the representations,
warranties and covenants made hereunder by EnteraBio, (c) the material breach by EnteraBio or its Affiliates of any agreement
or arrangement with a subcontractor performing its obligations under this Agreement pursuant to Section 3.2, and (d) other matters
that the Parties agree to in writing; except, in each case, to the extent such Losses result from clause (a), (b), or (c) of Section
10.1.2.

 

10.1.2   
By Amgen. Amgen agrees to defend EnteraBio, its Affiliates and their respective directors, officers, employees
and agents (the “EnteraBio Indemnified Parties”), at Amgen’s cost and expense, and will indemnify and
hold EnteraBio and the other EnteraBio Indemnified Parties harmless from and against any Losses to the extent resulting from any
Third Party Claims arising out of (a) the gross negligence or willful misconduct of Amgen, its Affiliates, or their respective
Sublicensees in connection with its activities under this Agreement; (b) the material breach of this Agreement or the representations,
warranties and covenants made hereunder by Amgen; (c) the material breach by Amgen or its Affiliates of any agreement or arrangement
with a subcontractor performing its obligations under this Agreement pursuant to Section 3.2, and or (d) the research, development,
manufacture or other Exploitation of any Product by or on behalf of Amgen, its Affiliates, or their respective Sublicensees (including
from product liability and intellectual property infringement claims); except, in each case, to the extent such Losses result
from clause (a), (b), (c) or (d) of Section 10.1.1.

 

10.1.3   
Procedure. The foregoing indemnity obligations shall be conditioned upon (x) the indemnified Party (“Indemnitee”)
promptly notifying the indemnifying Party (“Indemnitor”) in writing of the assertion or the commencement of
the relevant Third Party Claim (provided, however, that any failure or delay to notify shall not excuse any obligation
of the Indemnitor, except to the extent the Indemnitor is actually prejudiced thereby), (y) the Indemnitee granting the Indemnitor
sole management and control, at the Indemnitor’s sole expense, of the defense of such Third Party Claim and its settlement

 

    -33-

     

    

 

(provided,
however, that the Indemnitor shall not settle any such Third Party Claim without the prior written consent of the Indemnitee
if such settlement does not include a complete release from liability or if such settlement would involve the Indemnitee undertaking
an obligation (including the payment of money by the Indemnitee), would bind or impair the Indemnitee, or includes any admission
of wrongdoing by the Indemnitee or that any intellectual property or proprietary right of Indemnitee or this Agreement is invalid,
narrowed in scope or unenforceable, and (z) the Indemnitee reasonably cooperating with the Indemnitor (at the Indemnitee’s
expense). The Indemnitee shall have the right (at its own expense) to be present in person or through counsel at all legal proceedings
giving rise to the right of indemnification. Notwithstanding the foregoing, the Indemnitee will have the right to employ separate
counsel at the Indemnitee’s expense and to control its own defense of the applicable Third Party Claim only if: (i) there
are or may be legal defenses available to the Indemnitee that are different from or additional to those available to the Indemnitor
or (ii) in the reasonable opinion of counsel to the Indemnitee, a conflict or potential conflict exists between the Indemnitee
and the Indemnitor that would make such separate representation advisable. The Indemnitee shall not settle or compromise such
Third Party claim without the prior written consent of the Indemnitor, such consent not to be unreasonably withheld, conditioned
or delayed.

 

Article
11. limitations of liability

 

Section
11.1 LIMITATION OF DAMAGES. IN NO EVENT SHALL A PARTY BE LIABLE HEREUNDER TO THE OTHER PARTY FOR ANY PUNITIVE, INDIRECT,
SPECIAL, INCIDENTAL OR CONSEQUENTIAL DAMAGES (INCLUDING LOST REVENUE, LOST PROFITS, OR LOST SAVINGS) HOWEVER CAUSED AND UNDER
ANY THEORY, EVEN IF IT HAS NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. THE LIMITATIONS SET FORTH IN THIS SECTION 11.1 SHALL NOT
APPLY WITH RESPECT TO ANY BREACH OF ARTICLE 12. NOTHING IN THIS SECTION 11.1 IS INTENDED TO LIMIT OR RESTRICT THE INDEMNIFICATION
RIGHTS OR OBLIGATIONS OF A PARTY UNDER ARTICLE 10 WITH RESPECT TO ANY DAMAGES REQUIRED TO BE PAID TO A THIRD PARTY IN CONNECTION
WITH A THIRD PARTY CLAIM.

 

Section
11.2 Insurance. Each of the Parties will, at their own respective expense procure and maintain during the Term and
for [*] thereafter, insurance policies adequate to cover their obligations hereunder and consistent with the normal business practices
of prudent biopharmaceutical companies of similar size and scope (or reasonable self-insurance sufficient to provide materially
the same level and type of protection), and will upon request provide the other Party with a certificate of insurance in that
regard, along with any amendments and revisions thereto. Such insurance will not create a limit to either Party’s liability
hereunder.

 

Article
12. CONFIDENTIALITY

 

Section
12.1 Confidential Information.

 

12.1.1   
Confidential Information. Each Party (the “Receiving Party”) may receive during the course
and conduct of activities under this Agreement, certain proprietary or confidential information of the other Party (the “Disclosing
Party”) as furnished to the Receiving Party by or on behalf of the Disclosing Party. The term “Confidential
Information” means all ideas and information of any kind, whether in written, oral, graphical, machine-readable or other
form, whether or not marked as confidential or proprietary, which are transferred, disclosed or made available by Disclosing Party
or at the request of Receiving Party, including any of the foregoing of Affiliates or Third Parties.

 

    -34-

     

    

 

12.1.2   
Restrictions. During the Term and for [*] thereafter, Receiving Party will keep all Disclosing Party’s
Confidential Information in confidence with the same degree of care with which Receiving Party holds its own confidential information
(but in no event less than a commercially reasonable degree of care). Receiving Party will not use Disclosing Party’s Confidential
Information except in connection with the performance of its obligations and exercise of its rights under this Agreement. For
clarity, Amgen shall have the right to use any Confidential Information of EnteraBio in the Exploitation of a Product. Receiving
Party has the right to disclose Disclosing Party’s Confidential Information without Disclosing Party’s prior written
consent to Receiving Party’s Affiliates and their employees, subcontractors, consultants or agents who have a need to know
such Confidential Information in order to perform its obligations and exercise its rights under this Agreement and who are bound
by restrictions on use and disclosure consistent with this Section 12.1.2. Receiving Party will use diligent efforts to cause
those entities and persons to comply with the restrictions on use and disclosure in this Section 12.1.2. Receiving Party assumes
responsibility for those entities and persons maintaining Disclosing Party’s Confidential Information in confidence and
using same only for the purposes described herein.

 

12.1.3   
Exceptions. Receiving Party’s obligation of nondisclosure and the limitations upon the right to use the
Disclosing Party’s Confidential Information will not apply to the extent that Receiving Party can demonstrate that the Disclosing
Party’s Confidential Information: (a) was known to Receiving Party or any of its Affiliates prior to the time of disclosure
by Disclosing Party hereunder; (b) is or becomes public knowledge through no fault or omission of Receiving Party or any of its
Affiliates; (c) is obtained by Receiving Party or any of its Affiliates from a Third Party not known by the Receiving Party after
reasonable inquiry to be under an obligation of confidentiality to Disclosing Party; (d) has been independently discovered or
developed by employees, subcontractors, consultants or agents of Receiving Party or any of its Affiliates without the reference
to or use of Disclosing Party’s Confidential Information, as evidenced by contemporaneous written records; or (e) was released
from the restrictions set forth in this Agreement by express prior written consent of the Disclosing Party.

 

12.1.4   
Permitted Disclosures. Receiving Party may disclose Disclosing Party’s Confidential Information to the
extent (and only to the extent) such disclosure is reasonably necessary in the following instances:

 

		(a)	in
                                         order to comply with applicable Law (including any securities law or regulation or the
                                         rules of a securities exchange or as a requirement in filing for an International Nonproprietary
                                         Name (INN) or the like) or with a legal or administrative proceeding, or in connection
                                         with prosecuting or defending litigation;

 

		(b)	in
                                         connection with prosecuting and defending litigation, Marketing Approvals and other Regulatory
                                         Filings and communications, and filing, prosecuting and enforcing Patent Rights in connection
                                         with Receiving Party’s rights and obligations pursuant to this Agreement; and 

 

		(c)	[*];
                                         permitted acquirers or assignees; and investment bankers, investors and lenders;

  

    -35-

     

    

 

provided,
however, that (1) with respect to each of Sections 12.1.4(a) and 12.1.4(b), where reasonably possible, Receiving Party will
notify Disclosing Party of Receiving Party’s intent to make any disclosure pursuant thereto sufficiently prior to making
such disclosure so as to allow Disclosing Party adequate time to take whatever action it may deem appropriate to protect the confidentiality
of the information to be disclosed; and (2) with respect to Section 12.1.4(c), [*].

 

Section
12.2 Terms of this Agreement; Publicity.

 

12.2.1   
Restrictions. The Parties agree that the terms of this Agreement, including the identity of each Collaboration
Program, will be treated as Confidential Information of both Parties, and thus may be disclosed only as permitted by Section 12.1.4.
Except as required by Law or as permitted under Section 12.1.4, each Party agrees not to issue any press release or public statement
disclosing information relating to this Agreement or the transactions contemplated hereby or the terms hereof without the prior
written consent of the other Party, not to be unreasonably withheld, conditioned or delayed (or as such consent may need to be
obtained in accordance with Section 12.3). Notwithstanding the foregoing, a press release in the form attached hereto as Exhibit D
shall be issued by EnteraBio on or as promptly as practicable after the Effective Date.

 

12.2.2   
Review. Subject to Section 12.1.4, in the event either Party (the “Issuing Party”) desires
to issue a press release (other than as set forth on Exhibit D) or other public statement disclosing information relating
to this Agreement or the transactions contemplated hereby or the terms hereof, the Issuing Party will provide the other Party
(the “Reviewing Party”) with a copy of the proposed press release or public statement (the “Release”).
The Issuing Party will specify with each such Release, taking into account the urgency of the matter being disclosed, a reasonable
period of time within which the Receiving Party may provide any comments on such Release (but in no event less than ten (10) business
days). If the Reviewing Party provides any comments, the Parties will consult on such Release and work in good faith to prepare
a mutually acceptable Release. Either Party may subsequently publicly disclose any information previously contained in any Release,
provided that (a) the other Party provided its written consent hereto as stated in Section 12.2.1, and (b) circumstances have
not changed such that such previous disclosure is rendered inaccurate or misleading. For the avoidance of doubt (and notwithstanding
anything contained in this Agreement to the contrary), Amgen, in its sole discretion, may make disclosures relating to the development
or commercialization of a Product, including the results of research and any clinical trial conducted by Amgen or any health or
safety matter related to a Product.

 

Section
12.3 Publication. Amgen will have the sole right to publish and make scientific presentations with respect to Products,
and to issue press releases (except with respect to the terms of this Agreement, which is governed by Section 12.2) or make other
public disclosures regarding any such Products, and EnteraBio will not do so without Amgen’s prior written consent, except
as required by Law; provided, however, that any publication or presentation to be made by Amgen that names EnteraBio will
require the prior written consent of EnteraBio. The Party that is entitled hereunder to make a publication or presentation (the
“Publishing Party”) will deliver to the other Party (the “Non-Publishing Party”) a copy
of any proposed written publication or outline of presentation

 

    -36-

     

    

 

to
be made by the Publishing Party in advance of submission for publication or presentation at least thirty (30) days in advance
of submission (or, where a copy of such publication or presentation is not available at such time, a draft or outline of such
publication or a description of such presentation), and the Non-Publishing Party will have the right to: (a) require a delay in
submission of not more than sixty (60) days to enable patent applications protecting any product; and (b) prohibit disclosure
of any of its Confidential Information in any such proposed publication or presentation. If there is any dispute between the Parties
with regard to a proposed publication, presentation or other communication regarding this Agreement, such dispute shall be referred
to the JRC for resolution. Each Party agrees that it will not unreasonably withhold, condition or delay its consent to requests
for (i) extensions of the above timelines in the event that material late-breaking clinical data becomes available or (ii) shortening
of the above timelines if the requesting Party has a good faith belief that circumstances warrant such acceleration. The Parties
acknowledge and agree that all publications and presentations pursuant to this Section 12.3 shall comply with the International
Committee of Medical Journal Editors (ICMJE) Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly
Work in Medical Journals. Consistent with those guidelines, authorship will be based upon substantial contribution to the design,
analysis, interpretation of data, drafting and/or critically revising any publication(s) derived from this Agreement, and authors
must engage in the drafting of the publication or revise it critically for important intellectual content. Each party agrees to
maintain evidence of its compliance with the ICMJE guidelines for authorship, and that it will provide such evidence to the other
Party upon request.

 

Section
12.4 Relationship to the Confidentiality Agreement. This Agreement supersedes the Confidential Disclosure Agreement;
provided, however, that all “Confidential Information” disclosed or received by the Parties thereunder will
be deemed “Confidential Information” hereunder and will be subject to the terms and conditions of this Agreement.

 

Section
12.5 Attorney-Client Privilege. Neither Party is waiving, nor will be deemed to have waived or diminished, any of its
attorney work product protections, attorney-client privileges or similar protections and privileges recognized under the applicable
Law of any jurisdiction as a result of disclosing information pursuant to this Agreement, or any of its Confidential Information
(including Confidential Information related to pending or threatened litigation) to the Receiving Party, regardless of whether
the Disclosing Party has asserted, or is or may be entitled to assert, such privileges and protections. The Parties may become
joint defendants in proceedings to which the information covered by such protections and privileges relates and may determine
that they share a common legal interest in disclosure between them that is subject to such privileges and protections, and in
such event, may enter into a joint defense agreement setting forth, among other things, the foregoing principles but are not obligated
to do so.

 

Article
13. TERM & TERMINATION

 

Section
13.1 Term. The term of this Agreement shall commence on the Effective Date, and unless terminated earlier as provided
in this Article 13 or Section 4.5.2, shall continue in full force and effect, on a Product-by-Product basis, until expiration
of the last-to-expire Royalty Term with respect to such Product (the “Term”). On a country-by-country and Product-by-Product
basis, the licenses granted under this Agreement to Exploit all Products to a terminated Collaboration Program shall be fully
paid-up, irrevocable and non-exclusive upon the expiration of the Royalty Term in each country applicable to each such Product.

 

    -37-

     

    

 

Section
13.2 Termination by EnteraBio.

 

13.2.1   
Amgen Breach. EnteraBio will have the right to terminate this Agreement in the event of any material breach
by Amgen of any terms and conditions of this Agreement; provided, however, that such termination will not be effective
if such breach has been cured within ninety (90) days after written notice thereof is given by EnteraBio to Amgen specifying the
nature of the alleged breach. Notwithstanding the foregoing in this Section 13.2.1, in the event of a good faith dispute as to
whether performance has been made by either Party pursuant to this Agreement, the foregoing cure period with respect thereto will
be tolled pending final resolution of such dispute in accordance with the terms of this Agreement; provided, however, if
such dispute relates to payment, such tolling of the cure period will only apply with respect to payment of the disputed amounts,
and not with respect to any undisputed amount.

 

Section
13.3 Termination by Amgen.

 

13.3.1   
EnteraBio Breach. Amgen will have the right to terminate this Agreement in the event of any material breach
by EnteraBio of any terms and conditions of this Agreement; provided, however, that such termination will not be effective
if such breach has been cured within ninety (90) days after written notice thereof is given by Amgen to EnteraBio specifying the
nature of the alleged breach. . Notwithstanding the foregoing in this Section 13.3.1, in the event of a good faith dispute as
to whether performance has been made by either Party pursuant to this Agreement, including any good faith dispute as to any payment
due under this Agreement, the foregoing cure period with respect thereto will be tolled pending final resolution of such dispute
in accordance with the terms of this Agreement; provided, however, if such dispute relates to payment, such tolling of
the cure period will only apply with respect to payment of the disputed amounts, and not with respect to any undisputed amount.

 

13.3.2   
Discretionary Termination. [*]

 

Section
13.4 Effects of Termination. Upon termination by a Party, as applicable, under Section 4.5.2, Section 13.2 or Section
13.3 (provided that, to the extent this Agreement is terminated solely with respect to a particular Collaboration Program or Product,
then the remainder of this Section 13.4 shall only apply to the terminated Collaboration Program or Product):

 

13.4.1   
Ongoing Clinical Studies. The Termination Party will responsibly wind-down, in accordance with accepted biopharmaceutical
industry norms and ethical practices, any on-going clinical studies for which it has responsibility hereunder in which patient
dosing has commenced, and Amgen will be responsible for any costs and expenses reasonably associated with or actually incurred
with such wind-down.

 

13.4.2   
Termination of Licenses and Sublicense. All relevant licenses and sublicenses granted under Article 4, as of
the effective date of such termination, shall terminate automatically unless otherwise agreed by the Parties in writing.

 

    -38-

     

    

 

13.4.3   
Destruction of Confidential Information. Each Party shall destroy, at the other Party’s request, Confidential
Information that it has received from such other Party and is in its possession as of the effective date of expiration or termination
(with the exception of one copy of such Confidential Information, which may be retained by the legal department of the Party that
received such Confidential Information to confirm compliance with the non-use and non-disclosure provisions of this Agreement);
provided that each Party may retain and continue to use all such Confidential Information of the other Party to the extent necessary
to exercise any surviving rights, licenses or obligations under this Agreement. Notwithstanding the foregoing, a Party shall not
be required to destroy any computer files created during automatic system back up that are subsequently stored securely by it
and not readily accessible to its employees, consultants, or others who received Confidential Information under this Agreement.

 

13.4.4   
Prior Payments. Each Party shall pay all undisputed amounts then due and owing to the other Party as of the
termination date. In addition, Amgen shall pay EnteraBio all non-cancelable expenses and costs EnteraBio is obliged to pay and
which are to be reimbursed according to Section 3.1.

 

Section
13.5 Survival. In addition to the expiration or termination consequences set forth in Section 13.4 and the provisions
that are expressly stated to survive termination, the following provisions will survive termination or expiration of this Agreement:
Articles 1, 10, 11 and 14, Section 7.2 (with respect to a Milestone Events reached prior to such expiration or termination), Section
7.3 (with respect to sales made before such expiration or termination), Sections 7.4 through 7.9 inclusive (with respect to periods
with sales of Products made before such expiration or termination), Section 8.1, Sections 8.4 and 8.5 (with respect to any action
initiated prior to such expiration or termination), Sections 9.5, 12.1, 12.2, 12.3 (with respect to any paper or presentation
proposed, or any paper or presentation including data or results of clinical studies conducted, prior to such expiration or termination),
12.4, 12.5 (solely the first sentence) 13.4 and 13.5. Termination or expiration of this Agreement are neither Party’s exclusive
remedy and will not relieve the Parties of any liability or obligation which accrued hereunder prior to the effective date of
such termination or expiration nor preclude either Party from pursuing all rights and remedies it may have hereunder or at law
or in equity with respect to any breach of this Agreement nor prejudice either Party’s right to obtain performance of any
obligation. All other rights and obligations will terminate upon termination or expiration of this Agreement.

 

Article
14. MISCELLANEOUS

 

Section
14.1 Entire Agreement; Amendment. This Agreement and all Exhibits attached hereto constitute the entire agreement between
the Parties as to the subject matter hereof. All prior and contemporaneous negotiations, representations, warranties, agreements,
statements, promises and understandings with respect to the subject matter of this Agreement, including the Confidential Disclosure
Agreement, are hereby superseded and merged into, extinguished by and completely expressed by this Agreement. Neither of the Parties
shall be bound by or charged with any written or oral agreements, representations, warranties, statements, promises or understandings
not specifically set forth in this Agreement. No amendment, supplement or other modification to any provision of this Agreement
shall be binding unless in writing and signed by Amgen and EnteraBio.

 

    -39-

     

    

 

Section
14.2 Section 365(n) of the Bankruptcy Code. All rights and licenses granted under or pursuant to any section of this
Agreement are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code, licenses of rights
to “intellectual property” as defined under Section 101(35A) of the U.S. Bankruptcy Code to the extent permitted thereunder.
The Parties shall retain and may fully exercise all of their respective rights and elections under the U.S. Bankruptcy Code. Upon
the bankruptcy of any Party, the non-bankrupt Party shall further be entitled to a complete duplicate of (or complete access to,
as appropriate) any such intellectual property, and such, if not already in its possession, shall be promptly delivered to the
non-bankrupt Party, unless the bankrupt Party elects to continue, and continues, to perform all of its obligations under this
Agreement.

 

Section
14.3 Independent Contractors. The relationship between Amgen and EnteraBio created by this Agreement is solely that
of independent contractors. This Agreement does not create any agency, distributorship, employee-employer, partnership, joint
venture or similar business relationship between the Parties. No such Party is a legal representative of the other Party, and
no such Party can assume or create any obligation, representation, warranty or guarantee, express or implied, on behalf of the
other Party for any purpose whatsoever. Each such Party shall use its own discretion and shall have complete and authoritative
control over its employees and the details of performing its obligations under this Agreement.

 

Section
14.4 Governing Law; Disputes. This Agreement and its effect are subject to and shall be construed and enforced in accordance
with the law of the State of New York, without regard to its conflicts of laws, except as to any issue which depends upon the
validity, scope or enforceability of any Amgen Patent, EnteraBio Patent or Collaboration Patent, which issue shall be determined
in accordance with the laws of the country in which such patent was issued. If a dispute regarding this Agreement or the activities
contemplated hereby arises between the Parties, the Parties shall attempt to solve the issue through good faith discussions for
a period of at least sixty (60) days, and the Parties will use reasonable efforts to reach an amicable resolution of the issue
during such period. During such sixty (60)-day period, the Parties may agree to submit such dispute for non-binding mediation.
If, notwithstanding the efforts of the Parties in accordance with the previous sentence, after such sixty (60)-day period, a dispute
cannot be amicably resolved, then such dispute shall be finally settled under the Rules of Arbitration of the International Institute
for Conflict Prevention and Resolution by [*] arbitrators, of whom each Party shall designate [*], with the [*] arbitrator to
be designated by the [*] Party-appointed arbitrators. Such arbitration shall be conducted in New York, NY, U.S.A. The arbitration
shall be governed by the Federal Arbitration Act, 9 U.S.C.§1
et seq., and judgment upon the award rendered by the arbitrator(s) may be entered by any court having jurisdiction thereof.
The arbitrator shall not have the power to grant any award or remedy other than such awards or remedies that are available under
the applicable Law. Notwithstanding the foregoing, each Party understands and agrees that
a Party shall be entitled to seek injunctive and/or equitable relief and enforcement of any arbitration award from the applicable
courts in any appropriate jurisdiction.

 

    -40-

     

    

 

Section
14.5 Notice. Any notice required or permitted to be given by this Agreement shall be in writing, in English. Any and
all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall
be deemed given and effective if (a) delivered by hand or by overnight courier with tracking capabilities, (b) mailed postage
prepaid by first class, registered, or certified mail, or (c) delivered by facsimile followed by delivery via either of the methods
set forth in clauses (a) and (b) of this Section 14.5, in each case, addressed as set forth below unless changed by notice so
given:

 

	 	If
    to EnteraBio:	EnteraBio
    Ltd.
	 	 	Minrav
    Building, 5th Floor, PO Box 12117 
	 	 	Jerusalem
    91220
	 	 	Israel
	 	 	Attn:
    Philip Schwartz, CEO
	 	 	 
	 	 	with
    a copy (which shall not constitute notice) to:
	 	 	 
	 	 	Herzog,
    Fox & Neeman 
	 	 	Asia
    House, 4 Weizmann St. 
	 	 	Tel
    Aviv 6423904 
	 	 	Israel
	 	 	Attn:
    Yair Geva, Adv. and Tomer Farkash, Adv.
	 	 	 
	 	If
    to Amgen:	Amgen
    Inc.
	 	 	One
    Amgen Center Drive
	 	 	Thousand
    Oaks, CA 91320
	 	 	USA
	 	 	Attn:  [*]
	 	 	 
	 	 	with
    a copy (which shall not constitute notice) to:
	 	 	 
	 	 	One
    Amgen Center Drive
	 	 	Thousand
    Oaks, CA 91320
	 	 	USA
	 	 	Attn:  [*]

 

Any such
notice shall be deemed given on the date received, except any notice received after 5:00 p.m. (in the time zone of the receiving
Party) on a business day or received on a non-business day shall be deemed to have been received on the next business day. A Party
may add, delete, or change the Person or address to which notices should be sent at any time upon written notice delivered to
the Party’s notices in accordance with this Section 14.5.

 

Section
14.6 Compliance With Law; Severability. Nothing in this Agreement shall be construed to require the commission of any
act contrary to Law. If any one or more provisions of this Agreement is held to be invalid, illegal or unenforceable, the affected
provisions of this Agreement shall be curtailed and limited only to the extent necessary to bring it within the applicable legal
requirements and the validity, legality and enforceability of the remaining provisions of this Agreement shall not in any way
be affected or impaired thereby.

 

    -41-

     

    

 

Section
14.7 Non-Use of Names. EnteraBio shall not use the name, trademark, logo, or physical likeness of Amgen or any of its
respective officers, directors or employees, or any adaptation of any of them, in any advertising, promotional or sales literature,
without Amgen’s prior written consent. EnteraBio shall require its Affiliates to comply with the foregoing. Amgen shall
not use the name, trademark, logo, or physical likeness of EnteraBio or any of its officers, directors or employees, or any adaptation
of any of them, in any advertising, promotional or sales literature, without EnteraBio’s prior written consent. Amgen shall
require its Affiliates and Sublicensees to comply with the foregoing.

 

    -42-

     

    

 

Section
14.8 Successors and Assigns. Neither this Agreement nor any of the rights or obligations created herein may be assigned
by either Party, in whole or in part, without the prior written consent of the other Party, not to be unreasonably withheld, conditioned
or delayed except that either Party shall be free to assign this Agreement (a) to an Affiliate of such Party (for so long as such
Affiliate remains an Affiliate) provided that such Party shall remain liable and responsible to the other Party for the performance
and observance of all such duties and obligations by such Affiliate, or (b) in connection with any sale of all or substantially
all of the assets of the Party that relate to this Agreement to a Third Party, whether by merger, consolidation, divestiture,
restructure, sale of stock, sale of assets or otherwise (a “Sale Transaction”), provided that the party to
which this Agreement is assigned expressly agrees in writing to assume and be bound by all obligations of the assigning Party
under this Agreement. A copy of such written agreement by such assignee shall be provided to the non-assigning Party within ten
(10) calendar days of execution of such written agreement. This Agreement shall bind and inure to the benefit of the successors
and permitted assigns of the Parties hereto. Any attempted assignment of this Agreement in contravention of this Section 14.8
shall be null and void.

 

Section
14.9 Sale Transaction or Amgen Acquisition. In the event of (x) a Sale Transaction involving Amgen, or (y) the acquisition
by Amgen of all or substantially all of the business of a Third Party (together with any entities that were Affiliates of such
Third Party immediately prior to such acquisition, an “Amgen Acquiree”), whether by merger, sale of stock,
sale of assets or otherwise (an “Amgen Acquisition”), intellectual property rights of the acquiring party in
a Sale Transaction, if other than one of the Parties to this Agreement (together with any entities that were affiliates of such
Third Party immediately prior to such Sale Transaction, a “Third Party Acquirer”), or the Amgen Acquiree, as
applicable, shall not be included in the Patent Rights or Know-How licensed hereunder by Amgen to EnteraBio or otherwise subject
to this Agreement.

 

Section
14.10 Sale Transaction or EnteraBio Acquisition. In the event of (x) a Sale Transaction involving EnteraBio, or (y)
the acquisition by EnteraBio of all or substantially all of the business of a Third Party (together with any entities that were
Affiliates of such Third Party immediately prior to such acquisition, a “EnteraBio Acquiree”), whether by merger,
sale of stock, sale of assets or otherwise (a “EnteraBio Acquisition”), intellectual property rights of the
Third Party Acquirer in a Sale Transaction, or the EnteraBio Acquiree, as applicable, shall not be included in the Patent Rights
or Know-How licensed hereunder by EnteraBio to Amgen, or otherwise subject to this Agreement, except that to the extent the EnteraBio
Acquiree or Third Party Acquirer owns any Blocking Patents relative to any Product, EnteraBio shall and hereby does grant to Amgen
a non-exclusive license, [*] until the expiration of the last to expire of such Blocking Patents, on a country-by-country basis
or termination of this Agreement relative to such Product, whichever comes first, provided that at the time of such Sale Transaction
or EnteraBio Acquisition, such non-exclusive license rights are available for such grant and have not been exclusively licensed
to any Third Party.

 

    -43-

     

    

 

Section
14.11 Waivers. A Party’s consent to or waiver, express or implied, of any other Party’s breach of its obligations
hereunder shall not be deemed to be or construed as a consent to or waiver of any other breach of the same or any other obligations
of such breaching Party. A Party’s failure to complain of any act, or failure to act, by the other Party, to declare the
other Party in default, to insist upon the strict performance of any obligation or condition of this Agreement or to exercise
any right or remedy consequent upon a breach thereof, no matter how long such failure continues, shall not constitute a waiver
by such Party of its rights hereunder, of any such breach, or of any other obligation or condition. A Party’s consent in
any one instance shall not limit or waive the necessity to obtain such Party’s consent in any future instance and in any
event no consent or waiver shall be effective for any purpose hereunder unless such consent or waiver is in writing and signed
by the Party granting such consent or waiver.

 

Section
14.12 Rights upon Change of Control of EnteraBio. [*]

 

Section
14.13 No Third Party Beneficiaries. Nothing in this Agreement shall be construed as giving any Person, other than the
Parties hereto and their successors and permitted assigns, any right, remedy or claim under or in respect of this Agreement or
any provision hereof, except for the provisions of Article 10 (with respect to which the persons to which Article 10 applies shall
be Third Party beneficiaries for Article 10 only in accordance with the terms and conditions of Article 10).

 

Section
14.14 Headings; Exhibits. Article and Section headings used herein are for convenient reference only, and are not a
part of this Agreement. All Exhibits are incorporated herein by this reference.

 

Section
14.15 Interpretation. Except where the context otherwise requires, wherever used, the singular shall include the plural,
the plural the singular, and the use of any gender shall be applicable to all genders. The term “including” as used
herein means including, without limiting the generality of any description preceding such term. The word “will” shall
be construed to have the same meaning and effect as the word “shall”. The words “herein”, “hereof”
and “hereunder” and words of similar import will be construed to refer to this Agreement in its entirety and not to
any particular provision hereof. The word “or” means “and/or” unless the context dictates otherwise because
the subject of the conjunction are mutually exclusive. All references to “$” or “dollars” in this Agreement
means “U.S. dollars”. All references to a “business day” or “business days” in this Agreement
means any day other than a day which is a Saturday, a Sunday or any day banks are authorized or required to be closed in the State
of California. The language in all parts of this Agreement shall be deemed to be the language mutually chosen by the Parties.
The Parties and their counsel have cooperated in the drafting and preparation of this Agreement, and this Agreement therefore
shall not be construed against any Party by virtue of its role as the drafter thereof.

 

Section
14.16 Counterparts Electronic or Facsimile Signatures. This Agreement may be executed in any number of counterparts,
each of which shall be an original, but all of which together shall constitute one instrument. This Agreement may be executed
and delivered electronically or by facsimile and upon such delivery such electronic or facsimile signature will be deemed to have
the same effect as if the original signature had been delivered to the other Party.

 

[signature
page follows]

 

    -44-

     

    

 

IN
WITNESS WHEREOF, the Parties have executed this Agreement as of the date first set forth above.

 

AMGEN INC.

 

	By:	/s/ Raymond
    Deshaies
	Name: 	Raymond
Deshaies
	Title:	SVP Global Research

 

 

 

ENTERABIO
LTD.

 

	By:	/s/ Phillip
    Schwartz
	Name: 	Phillip
Schwartz
	Title:	 CEO

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[Signature
Page to Research Collaboration and License Agreement]

 

    

     

    

 

Exhibit
A

 

Press
Release

 

See attached.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    

     

    

 

	Entera
                           Bio Ltd.

         

        Phillip
        Schwartz,

        Chief
        Executive Officer

        Tel:
        +972-2- 532-7151

        phillip@enterabio.com
	INTERNATIONAL
                           INVESTOR RELATIONS

         

        Bob
        Yedid

        LifeSci
        Advisors, LLC

        646-597-6989

        bob@lifesciadvisors.com

 

 

Entera
Bio and Amgen Enter Strategic Research Collaboration in Inflammatory Disease and Other Serious Illnesses

 

- -
-

 

Amgen
will have the option to advance up to three large molecule programs using Entera’s oral delivery technology

 

- -
-

 

Entera
will be eligible to receive up to $270 million in clinical and commercial milestone payments

 

Jerusalem,
Israel – December 11 2018 – Entera Bio Ltd. (Nasdaq: ENTX) announced today that it has entered into a research
collaboration and license agreement with Amgen in inflammatory disease and other serious illnesses. Entera will use its proprietary
drug delivery platform to develop oral formulations for one preclinical large molecule program that Amgen has selected. Amgen
also has an option to select up to two additional programs to include in the collaboration.

 

“We are
excited to leverage our proprietary oral drug delivery platform in collaboration with Amgen, a leader in the development of large
molecule and biologic treatments in inflammatory disease and numerous other disorders,” stated Dr. Phillip Schwartz, chief
executive officer of Entera. “This collaboration is an important validation of our platform technology. Importantly, the
first program included in this agreement is very different from the Oral PTH (1-34) in Entera’s pipeline, highlighting the
broad applicability of our technology.”

 

Under the terms
of the agreement, Entera will receive a modest initial technology access fee from Amgen and will be responsible for preclinical
development at Amgen’s expense. Entera will be eligible to receive up to $270 million in aggregate payments, as well as
tiered royalties up to mid-single digits, upon achievement of various clinical and commercial milestones if Amgen decides to move
all of these programs forward. Amgen is responsible for clinical development, manufacturing and commercialization of any of the
resulting programs.

 

Entera will
retain all intellectual property rights to its drug delivery technology, which under this collaboration will be licensed to Amgen
exclusively for Amgen’s nominated drug targets. Amgen will retain all rights to its large molecules and any subsequent improvements.

 

    

     

    

 

About
Entera Bio Ltd.

 

Entera
Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule
therapeutics for use in orphan indications and other areas with significant unmet medical needs. The Company is initially applying
its technology to develop an oral formulation of a human parathyroid hormone analog, Oral PTH (1-34), for treatment of hypoparathyroidism
and osteoporosis.

 

++++++

 

Entera's
proprietary platform technology, consists of two components: a small molecule that enhances the absorption of a large molecule
therapeutic agents and a second component that “protects” the large molecule from digestion in the gastrointestinal
tract. This synergistic system is intended to increase oral bioavailability and decrease the variability associated with the oral
administration of large molecule biologics and synthetic protein therapeutic agents.

 

++++++

 

Currently,
biological entities and other large molecules can only be delivered via injections and or other non-oral pathways. However, oral
drug delivery is the easiest method for self-administering medications, offers patients greater dosing flexibility, and has the
highest patient acceptance and compliance rates as compared to all other routes of drug administration.

 

Forward
Looking Statements

 

This press
release contains "forward-looking statements." Words such as "may," "should," "could,"
"would," "predicts," "potential," "continue," "expects," "anticipates,"
"future," "intends," "plans," "believes," "estimates," and similar expressions,
as well as statements in future tense, often signify forward-looking statements. Forward-looking statements should not be read
as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be
achieved. Forward-looking statements are based on information that the Company has when those statements are made or management's
good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual
performance or results to differ materially from those expressed in or suggested by the forward-looking statements. For a discussion
of these and other risks that could cause such differences and that may affect the realization of forward-looking statements,
please refer to the "Special Note Regarding Forward-Looking Statements" and "Risk Factors" in the Company's
Registration Statement on Form F-1 and other filings with the Securities and Exchange Commission (SEC). Investors and security
holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation
to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

 

    

     

    

 

Contact:

Bob Yedid

LifeSci
Advisors, LLC 646-597-6989

bob@lifesciadvisors.com

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00294-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00294-of-00352.parquet"}]]